Anti-CCR8 antibodies and uses thereof
By developing anti-CCR8 antibodies, targeting CCR8 receptors to block the interaction between CCL1 and CCR8, the problem of difficulty in effectively targeting Treg cells in the prior art has been solved, effective inhibition of Treg cells is achieved, and anti-tumor immune response is enhanced.
Patent Information
- Application Number
- CN202380075366.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-23
- Filing Date
- 2023-10-26
- Publication Date
- 2025-06-13
AI Technical Summary
The prior art has difficulty effectively targeting regulatory T cells (Tregs) to treat cancer, especially with challenges in maintaining immune homeostasis and suppressing abnormal immune responses.
Anti-CCR8 antibodies and their antigen-binding fragments were developed to block the interaction between CCL1 and CCR8 by specifically binding to the CCR8 receptor, thereby inhibiting the immunosuppressive function of Treg cells.
By targeting CCR8, it can effectively reduce the number and function of tumor-resident Treg cells, enhance the anti-tumor immune response, and potentially improve the cancer treatment effect.
Smart Images

Figure CN120152988A_ABST
Abstract
Description
[0001] Priority Claim
[0002] This application claims the benefit of PCT / CN2022 / 128366, filed on October 28, 2022, and PCT / CN2023 / 114451, filed on August 23, 2023. The entire contents of the foregoing applications are incorporated herein by reference. Technical Field
[0003] The present disclosure relates to anti-CCR8 (chemokine (C-C motif) receptor 8) antibodies and their uses. Background Art
[0004] Regulatory T (Treg) cells suppress abnormal / overactive immune responses to self-antigens and non-self-antigens to maintain immune homeostasis. In tumor immunity, Treg cells are involved in the occurrence and progression of tumors by suppressing anti-tumor immunity.
[0005] The recent clinical and commercial success of anti-cancer antibodies has drawn extensive attention to antibody therapeutics, including those targeting Treg. There is a current need to develop anti-cancer antibodies targeting Treg for various antibody therapeutics for treating cancer. Summary of the Invention
[0006] The present disclosure relates to anti-CCR8 antibodies, antigen-binding fragments thereof, and their uses. In one aspect, the present disclosure provides a fully human anti-CCR8 antibody or an antigen-binding fragment thereof (e.g., produced by a genetically modified non-human animal having a humanized heavy-chain immunoglobulin locus and a humanized light-chain immunoglobulin locus).
[0007] In one aspect, the present disclosure relates to an antibody or an antigen-binding fragment thereof that binds to CCR8 (chemokine (C-C motif) receptor 8), the antibody or the antigen-binding fragment thereof comprising:
[0008] a heavy-chain variable region (VH) comprising complementarity-determining regions (CDR) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence having at least 80% identity with a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence having at least 80% identity with a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence having at least 80% identity with a selected VH CDR3 amino acid sequence; and
[0009] The variable light chain region (VL) comprising CDR1, 2 and 3, wherein the VL CDR1 region comprises an amino acid sequence having at least 80% identity with a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence having at least 80% identity with a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence having at least 80% identity with a selected VL CDR3 amino acid sequence,
[0010] wherein the selected VH CDR1, 2 and 3 amino acid sequences are one of the following:
[0011] (1) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:1, 2, 3 respectively;
[0012] (2) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:4, 5, 6 respectively;
[0013] (3) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:7, 8, 9 respectively;
[0014] (4) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:10, 11, 12 respectively;
[0015] (5) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:13, 14, 15 respectively;
[0016] (6) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:16, 17, 18 respectively;
[0017] (7) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:72, 73, 74 respectively;
[0018] (8) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:75, 76, 77 respectively;
[0019] (9) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:78, 79, 80 respectively;
[0020] (10) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:81, 82, 83 respectively;
[0021] (11) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:84, 85, 86 respectively;
[0022] (12) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 87, 88, and 89, respectively;
[0023] (13) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 90, 91, and 92, respectively;
[0024] (14) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 93, 94, and 95, respectively;
[0025] (15) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 96, 97, and 98, respectively;
[0026] (16) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 99, 100, and 101, respectively;
[0027] (17) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 102, 103, and 104, respectively;
[0028] (18) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 105, 106, and 107, respectively;
[0029] (19) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 144, 145, and 146, respectively;
[0030] (20) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 147, 148, and 149, respectively;
[0031] (21) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 150, 151, and 152, respectively;
[0032] (22) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 153, 154, and 155, respectively;
[0033] (23) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 156, 157, and 158, respectively;
[0034] (24) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 159, 160, and 161, respectively;
[0035] (25) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 162, 163, and 164, respectively;
[0036] (26) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 165, 166, and 167, respectively;
[0037] (27) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 168, 169, and 170, respectively;
[0038] (28) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 171, 172, and 173, respectively;
[0039] (29) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 174, 175, and 176, respectively;
[0040] (30) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 177, 178, and 179, respectively;
[0041] (31) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 219, 220, and 221, respectively;
[0042] (32) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 222, 223, and 224, respectively;
[0043] (33) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 225, 226, and 227, respectively;
[0044] (34) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 228, 229, and 230, respectively;
[0045] (35) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 231, 232, and 233, respectively;
[0046] (36) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 234, 235, and 236, respectively;
[0047] (37) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 237, 238, and 239, respectively;
[0048] (38) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 240, 241, and 242, respectively;
[0049] (39) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 243, 244, and 245, respectively;
[0050] (40) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 246, 247, and 248, respectively;
[0051] (41) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 249, 250, and 251, respectively;
[0052] (42) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 252, 253, and 254, respectively;
[0053] (43) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 255, 256, and 257, respectively; and
[0054] (44) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 258, 259, and 260, respectively;
[0055] wherein the selected VL CDR1, 2, and 3 amino acid sequences are one of the following:
[0056] (1) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 19, 20, and 21, respectively;
[0057] (2) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 22, 23, and 24, respectively;
[0058] (3) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 25, 26, and 27, respectively;
[0059] (4) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 28, 29, and 30, respectively;
[0060] (5) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 31, 32, and 33, respectively;
[0061] (6) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 34, 35, and 36, respectively;
[0062] (7) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 108, 109, and 110 respectively;
[0063] (8) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 111, 112, and 113 respectively;
[0064] (9) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 114, 115, and 116 respectively;
[0065] (10) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 117, 118, and 119 respectively;
[0066] (11) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 120, 121, and 122 respectively;
[0067] (12) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 123, 124, and 125 respectively;
[0068] (13) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 126, 127, and 128 respectively;
[0069] (14) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 129, 130, and 131 respectively;
[0070] (15) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 132, 133, and 134 respectively;
[0071] (16) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 135, 136, and 137 respectively;
[0072] (17) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 138, 139, and 140 respectively;
[0073] (18) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 141, 142, and 143 respectively;
[0074] (19) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 180, 181, and 182 respectively;
[0075] (20) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 183, 184, and 185, respectively;
[0076] (21) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 186, 187, and 188, respectively;
[0077] (22) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 189, 190, and 191, respectively;
[0078] (23) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 192, 193, and 194, respectively;
[0079] (24) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 195, 196, and 197, respectively;
[0080] (25) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 198, 199, and 200, respectively;
[0081] (26) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 201, 202, and 203, respectively;
[0082] (27) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 204, 205, and 206, respectively;
[0083] (28) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 207, 208, and 209, respectively;
[0084] (29) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 210, 211, and 212, respectively; and
[0085] (30) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 213, 214, and 215, respectively.
[0086] In one aspect, the present disclosure relates to an antibody or an antigen-binding fragment thereof that binds to CCR8 (chemokine (C-C motif) receptor 8), the antibody or the antigen-binding fragment thereof comprising:
[0087] A heavy chain variable region (VH) comprising complementarity determining regions (CDR) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR3 amino acid sequence; and
[0088] A light chain variable region (VL) comprising CDR1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR3 amino acid sequence,
[0089] wherein the selected VH CDR1, 2, and 3 amino acid sequences are one of the following:
[0090] (1) The selected VH CDR1 is SYVMH (SEQ ID NO:99); the selected VH CDR2 is VISYX 1 X 2 SDKYYADSVKG (SEQ ID NO:100); the selected VH CDR3 is
[0091] GRGYRYGQSYYYGMDV (SEQ ID NO:101);
[0092] (2) The selected VH CDR1 is SYVVH (SEQ ID NO:102); the selected VH CDR2 is VISYX 1 X 2 DNKFYADSVKG (SEQ ID NO:103); the selected VH CDR3 is
[0093] GRX 5 YX 6 X 7 YYGLDV (SEQ ID NO:104);
[0094] (3) The selected VH CDR1 is TYVMH (SEQ ID NO:105); the selected VH CDR2 is VISYX 1 X 2NNKYYADSVKG (SEQ ID NO:106); The selected VH CDR3 is GRSYVNYYGLDV (SEQ ID NO:107);
[0095] (4) The selected VH CDR1 is GFSFSSY (SEQ ID NO:171); The selected VH CDR2 is SYX 1 X 2 SD (SEQID NO:172); The selected VH CDR3 is GRGYRYGQSYYYGMDV (SEQ ID NO:173);
[0096] (5) The selected VH CDR1 is GFTFSSY (SEQ ID NO:174); The selected VH CDR2 is SYX 1 X 2 DN (SEQID NO:175); The selected VH CDR3 is GRX 5 YX 6 X 7 YYGLDV (SEQ ID NO:176); and
[0097] (6) The selected VH CDR1 is GFTFSTY (SEQ ID NO:177); The selected VH CDR2 is SYX 1 X 2 NN (SEQID NO:178); The selected VH CDR3 is GRSYVNYYGLDV (SEQ ID NO:179);
[0098] wherein the selected VL CDR1, 2, and 3 amino acid sequences are one of the following:
[0099] (1) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:135); The selected VL CDR2 is EVSNRFS (SEQ ID NO:136); The selected VL CDR3 is MQSIKLPLT (SEQ ID NO:137);
[0100] (2) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:138); The selected VL CDR2 is EVSNRFS (SEQ ID NO:139); The selected VL CDR3 is MQSLKVPPT (SEQ ID NO:140);
[0101] (3) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:141); the selected VL CDR2 is EVSNRFS (SEQ ID NO:142); the selected VL CDR3 is MQSVKIPLT (SEQ ID NO:143);
[0102] (4) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:207); the selected VL CDR2 is EVSNRFS (SEQ ID NO:208); the selected VL CDR3 is MQSIKLPLT (SEQ ID NO:209);
[0103] (5) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:210); the selected VL CDR2 is EVSNRFS (SEQ ID NO:211); the selected VL CDR3 is MQSLKVPPT (SEQ ID NO:212); and
[0104] (6) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:213); the selected VL CDR2 is EVSNRFS (SEQ ID NO:214); the selected VL CDR3 is MQSVKIPLT (SEQ ID NO:215);
[0105] wherein X in each sequence 1 and X 3 are independently selected from the group consisting of D, S and A,
[0106] wherein X in each sequence 2 and X 4 are independently selected from the group consisting of G and A,
[0107] wherein X in SEQ ID NO:104 or 176 5 is independently selected from the group consisting of N and S,
[0108] wherein X in SEQ ID NO:104 or 176 6 is independently selected from the group consisting of Y and V,
[0109] wherein X in SEQ ID NO: 104 or 176 7 is independently selected from the group consisting of Y and N.
[0110] In some embodiments, the selected VH CDR1, 2, and 3 amino acid sequences and the selected VL CDR1, 2, and 3 amino acid sequences are one of the following:
[0111] (1) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 1, 2, and 3, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 19, 20, and 21, respectively;
[0112] (2) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 4, 5, and 6, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 22, 23, and 24, respectively;
[0113] (3) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 7, 8, and 9, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 25, 26, and 27, respectively;
[0114] (4) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 10, 11, and 12, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 28, 29, and 30, respectively;
[0115] (5) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 13, 14, and 15, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 31, 32, and 33, respectively;
[0116] (6) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 16, 17, and 18, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NOs: 34, 35, and 36, respectively;
[0117] (7) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:1, 2, and 3, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:22, 23, and 24, respectively;
[0118] (8) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:1, 2, and 3, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:25, 26, and 27, respectively;
[0119] (9) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:4, 5, and 6, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:19, 20, and 21, respectively;
[0120] (10) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:4, 5, and 6, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:25, 26, and 27, respectively;
[0121] (11) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:7, 8, and 9, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:19, 20, and 21, respectively;
[0122] (12) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:7, 8, and 9, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:22, 23, and 24, respectively;
[0123] (13) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:10, 11, and 12, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:31, 32, and 33, respectively;
[0124] (14) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 10, 11, and 12, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 34, 35, and 36, respectively;
[0125] (15) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 13, 14, and 15, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 28, 29, and 30, respectively;
[0126] (16) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 13, 14, and 15, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 34, 35, and 36, respectively;
[0127] (17) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 16, 17, and 18, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 28, 29, and 30, respectively; and
[0128] (18) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 16, 17, and 18, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively.
[0129] In some embodiments, the selected VH CDR1, 2, and 3 amino acid sequences and the selected VL CDR1, 2, and 3 amino acid sequences are one of the following:
[0130] (1) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 1, 2, and 3, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 114, 115, and 116, respectively;
[0131] (2) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 72, 73, and 74, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 114, 115, and 116, respectively;
[0132] (3) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:72, 73, and 74, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:108, 109, and 110, respectively;
[0133] (4) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:78, 79, and 80, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:114, 115, and 116, respectively;
[0134] (5) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:75, 76, and 77, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:111, 112, and 113, respectively;
[0135] (6) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:10, 11, and 12, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:186, 187, and 188, respectively;
[0136] (7) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:144, 145, and 146, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:186, 187, and 188, respectively;
[0137] (8) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:144, 145, and 146, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:180, 181, and 182, respectively;
[0138] (9) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:150, 151, and 152, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO:186, 187, and 188, respectively;
[0139] (10) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 147, 148, and 149, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 183, 184, and 185, respectively;
[0140] (11) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 72, 73, and 74, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 25, 26, and 27, respectively;
[0141] (12) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 144, 145, and 146, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 34, 35, and 36, respectively;
[0142] (13) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 219, 220, and 221, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively;
[0143] (14) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 222, 223, and 224, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively;
[0144] (15) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 225, 226, and 227, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively;
[0145] (16) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 228, 229, and 230, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively;
[0146] (17) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 231, 232, and 233, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively;
[0147] (18) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 234, 235, and 236, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively;
[0148] (19) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 237, 238, and 239, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively;
[0149] (20) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 240, 241, and 242, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively;
[0150] (21) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 243, 244, and 245, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively;
[0151] (22) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 246, 247, and 248, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively;
[0152] (23) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 249, 250, and 251, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively;
[0153] (24) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 252, 253, and 254, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively;
[0154] (25) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 255, 256, and 257, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively; and
[0155] (26) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 258, 259, and 260, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively.
[0156] In some embodiments, the antibody or antigen-binding fragment specifically binds to human CCR8, murine CCR8, or simian CCR8.
[0157] In some embodiments, the antibody or antigen-binding fragment is a human or humanized antibody or an antigen-binding fragment thereof (e.g., a human IgG1 antibody).
[0158] In some embodiments, the antibody or antigen-binding fragment is a single-chain variable fragment (scFv), a single-arm antibody, or a multispecific antibody (e.g., a bispecific antibody).
[0159] In one aspect, the present disclosure relates to a nucleic acid comprising a polynucleotide encoding a polypeptide, the polypeptide comprising: an immunoglobulin heavy chain or a fragment thereof containing a heavy chain variable region (VH), the VH comprising complementarity-determining regions (CDR) 1, 2, and 3, and wherein the VH binds to CCR8 when paired with a light chain variable region (VL),
[0160] wherein the VH CDR1, 2, and 3 amino acid sequences are one of the following:
[0161] (1) The selected VH CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 1, 2, and 3, respectively,
[0162] (2) The selected VH CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 4, 5, and 6, respectively;
[0163] (3) The selected VH CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 7, 8, and 9, respectively;
[0164] (4) The selected VH CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 10, 11, and 12, respectively;
[0165] (5) The selected VH CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 13, 14, and 15, respectively;
[0166] (6) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:16, 17, and 18 respectively;
[0167] (7) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:72, 73, and 74 respectively;
[0168] (8) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:75, 76, and 77 respectively;
[0169] (9) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:78, 79, and 80 respectively;
[0170] (10) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:81, 82, and 83 respectively;
[0171] (11) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:84, 85, and 86 respectively;
[0172] (12) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:87, 88, and 89 respectively;
[0173] (13) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:90, 91, and 92 respectively;
[0174] (14) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:93, 94, and 95 respectively;
[0175] (15) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:96, 97, and 98 respectively;
[0176] (16) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:99, 100, and 101 respectively;
[0177] (17) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:102, 103, and 104 respectively;
[0178] (18) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:105, 106, and 107 respectively;
[0179] (19) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 144, 145, and 146 respectively;
[0180] (20) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 147, 148, and 149 respectively;
[0181] (21) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 150, 151, and 152 respectively;
[0182] (22) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 153, 154, and 155 respectively;
[0183] (23) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 156, 157, and 158 respectively;
[0184] (24) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 159, 160, and 161 respectively;
[0185] (25) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 162, 163, and 164 respectively;
[0186] (26) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 165, 166, and 167 respectively;
[0187] (27) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 168, 169, and 170 respectively;
[0188] (28) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 171, 172, and 173 respectively;
[0189] (29) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 174, 175, and 176 respectively;
[0190] (30) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 177, 178, and 179 respectively;
[0191] (31) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 219, 220, and 221 respectively;
[0192] (32) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 222, 223, and 224, respectively;
[0193] (33) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 225, 226, and 227, respectively;
[0194] (34) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 228, 229, and 230, respectively;
[0195] (35) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 231, 232, and 233, respectively;
[0196] (36) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 234, 235, and 236, respectively;
[0197] (37) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 237, 238, and 239, respectively;
[0198] (38) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 240, 241, and 242, respectively;
[0199] (39) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 243, 244, and 245, respectively;
[0200] (40) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 246, 247, and 248, respectively;
[0201] (41) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 249, 250, and 251, respectively;
[0202] (42) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 252, 253, and 254, respectively;
[0203] (43) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 255, 256, and 257, respectively; and
[0204] (44) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 258, 259, and 260, respectively;
[0205] wherein the VL amino acid sequence is selected from the group consisting of SEQ ID NO: 40, 41, 42, 66, 67, and 68.
[0206] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide that comprises an immunoglobulin heavy chain or a fragment thereof that comprises a VH, and the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 1, 2, and 3, respectively.
[0207] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide that comprises an immunoglobulin heavy chain or a fragment thereof that comprises a VH, and the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 4, 5, and 6, respectively.
[0208] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide that comprises an immunoglobulin heavy chain or a fragment thereof that comprises a VH, and the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 7, 8, and 9, respectively.
[0209] In one aspect, the present disclosure relates to a nucleic acid comprising a polynucleotide encoding a polypeptide that comprises: an immunoglobulin heavy chain or a fragment thereof that comprises a light chain variable region (VL), the VL comprising complementarity determining regions (CDR) 1, 2, and 3, and wherein the VL binds CCR8 when paired with a heavy chain variable region (VH).
[0210] wherein the selected VL CDR1, 2, and 3 amino acid sequences are one of the following:
[0211] (1) the selected VL CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 19, 20, 21, respectively;
[0212] (2) the selected VL CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 22, 23, 24, respectively;
[0213] (3) the selected VL CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 25, 26, 27, respectively;
[0214] (4) the selected VL CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 28, 29, 30, respectively;
[0215] (5) the selected VL CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 31, 32, 33, respectively;
[0216] (6) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:34, 35, and 36 respectively;
[0217] (7) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:108, 109, and 110 respectively;
[0218] (8) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:111, 112, and 113 respectively;
[0219] (9) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:114, 115, and 116 respectively;
[0220] (10) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:117, 118, and 119 respectively;
[0221] (11) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:120, 121, and 122 respectively;
[0222] (12) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:123, 124, and 125 respectively;
[0223] (13) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:126, 127, and 128 respectively;
[0224] (14) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:129, 130, and 131 respectively;
[0225] (15) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:132, 133, and 134 respectively;
[0226] (16) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:135, 136, and 137 respectively;
[0227] (17) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:138, 139, and 140 respectively;
[0228] (18) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:141, 142, and 143 respectively;
[0229] (19) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 180, 181, and 182, respectively;
[0230] (20) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 183, 184, and 185, respectively;
[0231] (21) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 186, 187, and 188, respectively;
[0232] (22) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 189, 190, and 191, respectively;
[0233] (23) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 192, 193, and 194, respectively;
[0234] (24) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 195, 196, and 197, respectively;
[0235] (25) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 198, 199, and 200, respectively;
[0236] (26) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 201, 202, and 203, respectively;
[0237] (27) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 204, 205, and 206, respectively;
[0238] (28) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 207, 208, and 209, respectively;
[0239] (29) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 210, 211, and 212, respectively; and
[0240] (30) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 213, 214, and 215, respectively,
[0241] wherein the VH amino acid sequence is selected from the group consisting of SEQ ID NO: 37, 38, 39, 63, 64, 65, 69, 70, 71, 216, 261, 262, 263, 264, 265, 266, and 267.
[0242] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide that comprises an immunoglobulin light chain containing VL or a fragment thereof, wherein the VL comprises CDR1, 2, and 3 having the amino acid sequences set forth in SEQ ID NO: 19, 20, and 21, respectively.
[0243] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide that comprises an immunoglobulin light chain containing VL or a fragment thereof, wherein the VL comprises CDR1, 2, and 3 having the amino acid sequences set forth in SEQ ID NO: 22, 23, and 24, respectively.
[0244] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide that comprises an immunoglobulin light chain containing VL or a fragment thereof, wherein the VL comprises CDR1, 2, and 3 having the amino acid sequences set forth in SEQ ID NO: 25, 26, and 27, respectively.
[0245] In some embodiments, the VH specifically binds to human CCR8, mouse CCR8, or monkey CCR8 when paired with VL, or the VL specifically binds to human CCR8, mouse CCR8, or monkey CCR8 when paired with VH.
[0246] In some embodiments, the immunoglobulin heavy chain or fragment thereof is a human or humanized immunoglobulin heavy chain or fragment thereof, and the immunoglobulin light chain or fragment thereof is a human or humanized immunoglobulin light chain or fragment thereof.
[0247] In some embodiments, the nucleic acid encodes a single-chain variable fragment (scFv), a single-arm antibody, or a multispecific antibody (e.g., a bispecific antibody).
[0248] In some embodiments, the nucleic acid is cDNA.
[0249] In one aspect, the present disclosure relates to a vector that comprises one or more of the nucleic acids described herein.
[0250] In one aspect, the present disclosure relates to a vector that comprises two of the nucleic acids described herein, wherein the vector encodes a VH region and a VL region that together bind CCR8.
[0251] In one aspect, the present disclosure relates to a pair of vectors, wherein each vector comprises one of the nucleic acids described herein, and wherein the pair of vectors together encode a VH region and a VL region that together bind CCR8.
[0252] In one aspect, the present disclosure relates to a cell that comprises the vector or pair of vectors described herein.
[0253] In some embodiments, the cell is a CHO cell.
[0254] In one aspect, the present disclosure relates to a cell that comprises one or more nucleic acids described herein.
[0255] In one aspect, the present disclosure relates to a cell that comprises two nucleic acids described herein.
[0256] In some embodiments, the two nucleic acids jointly encode a VH region and a VL region, and the VH region and the VL region together bind to CCR8.
[0257] In one aspect, the present disclosure relates to a method for producing an antibody or an antigen-binding fragment thereof, the method comprising:
[0258] (a) culturing the cell under conditions sufficient for the cell to produce the antibody or antigen-binding fragment described herein; and
[0259] (b) collecting the antibody or antigen-binding fragment produced by the cell.
[0260] In one aspect, the present disclosure relates to an antibody or an antigen-binding fragment thereof that binds to CCR8, the antibody or antigen-binding fragment thereof comprising
[0261] a heavy chain variable region (VH) comprising an amino acid sequence having at least 80% identity to a selected VH sequence, and a light chain variable region (VL) comprising an amino acid sequence having at least 80% identity to a selected VL sequence,
[0262] wherein the selected VH sequence is selected from the group consisting of SEQ ID NO: 37, 38, 39, 63, 64, 65, 69, 70, 71, 216, 261, 262, 263, 264, 265, 266, and 267,
[0263] wherein the selected VL sequence is selected from the group consisting of SEQ ID NO: 40, 41, 42, 66, 67, and 68.
[0264] In some embodiments, the VH sequence and the VL sequence are one of the following:
[0265] (1) the VH comprises the sequence of SEQ ID NO: 37 and the VL comprises the sequence of SEQ ID NO: 40;
[0266] (2) the VH comprises the sequence of SEQ ID NO: 38 and the VL comprises the sequence of SEQ ID NO: 41;
[0267] (3) the VH comprises the sequence of SEQ ID NO: 39 and the VL comprises the sequence of SEQ ID NO: 42;
[0268] (4) The VH comprises the sequence of SEQ ID NO: 37, and the VL comprises the sequence of SEQ ID NO: 41;
[0269] (5) The VH comprises the sequence of SEQ ID NO: 37, and the VL comprises the sequence of SEQ ID NO: 42;
[0270] (6) The VH comprises the sequence of SEQ ID NO: 38, and the VL comprises the sequence of SEQ ID NO: 40;
[0271] (7) The VH comprises the sequence of SEQ ID NO: 38, and the VL comprises the sequence of SEQ ID NO: 42;
[0272] (8) The VH comprises the sequence of SEQ ID NO: 39, and the VL comprises the sequence of SEQ ID NO: 40;
[0273] (9) The VH comprises the sequence of SEQ ID NO: 39, and the VL comprises the sequence of SEQ ID NO: 41;
[0274] (10) The VH comprises the sequence of SEQ ID NO: 37, and the VL comprises the sequence of SEQ ID NO: 68;
[0275] (11) The VH comprises the sequence of SEQ ID NO: 63, and the VL comprises the sequence of SEQ ID NO: 68;
[0276] (12) The VH comprises the sequence of SEQ ID NO: 63, and the VL comprises the sequence of SEQ ID NO: 66;
[0277] (13) The VH comprises the sequence of SEQ ID NO: 65, and the VL comprises the sequence of SEQ ID NO: 68;
[0278] (14) The VH comprises the sequence of SEQ ID NO: 64, and the VL comprises the sequence of SEQ ID NO: 67;
[0279] (15) The VH comprises the sequence of SEQ ID NO: 63, and the VL comprises the sequence of SEQ ID NO: 42;
[0280] (16) The VH comprises the sequence of SEQ ID NO: 216, and the VL comprises the sequence of SEQ ID NO: 42;
[0281] (17) The VH comprises the sequence of SEQ ID NO: 261, and the VL comprises the sequence of SEQ ID NO: 41;
[0282] (18) The VH comprises the sequence of SEQ ID NO: 262, and the VL comprises the sequence of SEQ ID NO: 41;
[0283] (19) The VH comprises the sequence of SEQ ID NO: 263, and the VL comprises the sequence of SEQ ID NO: 41;
[0284] (20) The VH comprises the sequence of SEQ ID NO: 264, and the VL comprises the sequence of SEQ ID NO: 41;
[0285] (21) The VH comprises the sequence of SEQ ID NO: 265, and the VL comprises the sequence of SEQ ID NO: 41;
[0286] (22) The VH comprises the sequence of SEQ ID NO: 266, and the VL comprises the sequence of SEQ ID NO: 41; and
[0287] (23) The VH comprises the sequence of SEQ ID NO: 267, and the VL comprises the sequence of SEQ ID NO: 41.
[0288] In some embodiments, the antibody or antigen-binding fragment specifically binds to human CCR8, murine CCR8, or simian CCR8.
[0289] In some embodiments, the antibody or antigen-binding fragment is a human or humanized antibody or an antigen-binding fragment thereof.
[0290] In some embodiments, the antibody or antigen-binding fragment is a single-chain variable fragment (scFv), a single-arm antibody, or a multispecific antibody (e.g., a bispecific antibody).
[0291] In one aspect, the present disclosure relates to an antibody or an antigen-binding fragment thereof that binds to CCR8, the antibody or antigen-binding fragment comprising a heavy-chain variable region (VH) containing VH CDR1, 2, 3 and a light-chain variable region (VL) containing VL CDR1, 2, 3, wherein the VH CDR1, 2, 3 and the VL CDR1, 2, 3 are identical to the complementary determining regions in the antibody or antigen-binding fragment described herein.
[0292] In some embodiments, the VH CDR1, 2, 3 are identical to the complementarity determining regions in SEQ ID NO: 37, 38, 39, 63, 64, 65, 69, 70, 71, 216, 261, 262, 263, 264, 265, 266, or 267, and the VL CDR1, 2, 3 are identical to the complementarity determining regions in SEQ ID NO: 40, 41, 42, 66, 67, or 68.
[0293] In one aspect, the present disclosure relates to an antibody or an antigen-binding fragment thereof that cross-competes with the antibodies or antigen-binding fragments thereof described herein.
[0294] In one aspect, the present disclosure relates to an antibody-drug conjugate comprising an antibody or an antigen-binding fragment thereof described herein covalently bound to a therapeutic agent.
[0295] In some embodiments, the therapeutic agent is a cytotoxic agent or a cell growth inhibitor.
[0296] In one aspect, the present disclosure relates to a method of treating a subject having cancer, the method comprising: administering to the subject a therapeutically effective amount of a composition comprising an antibody or an antigen-binding fragment thereof described herein or an antibody-drug conjugate described herein.
[0297] In some embodiments, the subject has a solid tumor.
[0298] In some embodiments, the cancer is breast cancer, melanoma, non-small cell lung cancer, lung adenocarcinoma, colon cancer, or colorectal cancer (e.g., colorectal adenocarcinoma).
[0299] In some embodiments, the cancer is resistant to treatment with a PD-1 pathway inhibitor.
[0300] In some embodiments, the method further comprises administering to the subject a PD-1 pathway inhibitor.
[0301] In some embodiments, the PD-1 pathway inhibitor is an anti-PD-1 antibody (e.g., Pembrolizumab, Nivolumab, or Cemiplimab).
[0302] In some embodiments, the PD-1 pathway inhibitor is an anti-PD-L1 antibody (e.g., Atezolizumab, Avelumab, or Durvalumab).
[0303] In one aspect, the present disclosure relates to a method of reducing the tumor growth rate, the method comprising contacting tumor cells with an effective amount of a composition comprising an antibody or an antigen-binding fragment thereof described herein or an antibody-drug conjugate described herein.
[0304] In one aspect, the present disclosure relates to a method of killing tumor cells, the method comprising contacting the tumor cells with an effective amount of a composition comprising an antibody or antigen-binding fragment thereof as described herein or an antibody-drug conjugate as described herein.
[0305] In one aspect, the present disclosure relates to a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof as described herein and a pharmaceutically acceptable carrier.
[0306] In one aspect, the present disclosure relates to a pharmaceutical composition comprising an antibody-drug conjugate as described herein and a pharmaceutically acceptable carrier.
[0307] As used herein, the term "cancer" refers to cells having the ability to grow autonomously. Examples of such cells include cells having an abnormal state or condition characterized by rapid proliferative cell growth. The term is intended to include cancerous growths (e.g., tumors), carcinogenic processes, metastatic tissues, and malignantly transformed cells, tissues, or organs, regardless of their histopathological type or stage of invasion. Also included are malignancies of various organ systems, such as the respiratory, cardiovascular, renal, reproductive, hematopoietic, nervous, hepatic, gastrointestinal, and endocrine systems; and adenocarcinomas, which include malignancies such as most colon cancers, renal cell carcinomas, prostate cancers, and / or testicular tumors, non-small cell lung cancers, and small intestine cancers. "Naturally occurring" cancers include any cancers not experimentally induced by implanting cancer cells into a subject, and include, for example, spontaneously occurring cancers, cancers caused by a patient's exposure to a carcinogen, cancers caused by inserting a transgenic oncogene or knocking out a tumor suppressor gene, and cancers caused by an infection (e.g., viral infection). The term "carcinoma" is well recognized in the art and refers to a malignancy of epithelial or endocrine tissue. The term also includes carcinosarcomas, which include malignancies composed of carcinoma and sarcoma tissues. "Adenocarcinoma" refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures. The term "sarcoma" is well recognized in the art and refers to a malignancy of mesenchymal origin. The term "hematopoietic neoplastic disease" includes diseases involving proliferating / neoplastic cells of hematopoietic origin. Hematopoietic neoplastic diseases can be caused by myeloid cells, lymphoid cells, or erythroid cells or their progenitor cells. Blood cancers are cancers that originate from cells of hematopoietic tissues such as the bone marrow or the immune system. Examples of blood cancers include, for example, leukemia, lymphoma, and multiple myeloma, among others.
[0308] As used herein, the term "antibody" refers to any antigen-binding molecule that contains at least one (e.g., one, two, three, four, five, or six) complementarity-determining region (CDR) (e.g., any one of the three CDRs from an immunoglobulin light chain or any one of the three CDRs from an immunoglobulin heavy chain) and is capable of specifically binding to an epitope. Non-limiting examples of antibodies include: monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), single-chain antibodies, chimeric antibodies, human antibodies, and humanized antibodies. In some embodiments, an antibody may contain the Fc region of a human antibody. The term antibody also includes derivatives such as bispecific antibodies, single-chain antibodies, heavy-chain antibodies, diabodies, linear antibodies, and multispecific antibodies formed from antibody fragments.
[0309] As used herein, the term "antigen-binding fragment" refers to a portion of a full-length antibody, wherein that portion of the antibody is capable of specifically binding to an antigen. In some embodiments, the antigen-binding fragment contains at least one variable domain (e.g., the variable domain of a heavy chain or the variable domain of a light chain). Non-limiting examples of antibody fragments include, for example, Fab, Fab', F(ab') 2 , VHH, and Fv fragments.
[0310] As used herein, the term "human antibody" refers to an antibody encoded by endogenous nucleic acid derived from a human (e.g., a rearranged human immunoglobulin heavy or light chain locus). In some embodiments, a human antibody is harvested from a human or produced in a human cell culture (e.g., a human hybridoma cell). In some embodiments, a human antibody is produced in a non-human cell (e.g., a mouse or hamster cell line). In some embodiments, a human antibody is produced in a bacterial or yeast cell. In some embodiments, a human antibody is produced in a transgenic non-human animal (e.g., a cow) containing an unrearranged or rearranged human immunoglobulin locus (e.g., a heavy or light chain human immunoglobulin locus).
[0311] As used herein, the term "chimeric antibody" refers to an antibody that contains sequences present in at least two different species (e.g., an antibody from two different mammalian species, such as a human and a mouse antibody). A non-limiting example of a chimeric antibody is an antibody that contains the variable domain sequence (e.g., all or part of the light chain and / or heavy chain variable domain sequence) of a non-human (e.g., mouse) antibody and the constant domain of a human antibody. Other examples of chimeric antibodies are described herein and are known in the art.
[0312] As used herein, the term "humanized antibody" refers to a non-human antibody that contains a minimal sequence derived from a non-human (e.g., murine) immunoglobulin and contains a sequence derived from a human immunoglobulin. In a non-limiting example, a humanized antibody is a human antibody (the recipient antibody) in which the residues of the hypervariable regions (e.g., CDRs) of the recipient antibody are replaced with the residues of the hypervariable regions (e.g., CDRs) from a non-human antibody (e.g., the donor antibody), such as a murine, rat, or rabbit antibody, having the desired specificity, affinity, and potency. In some embodiments, the Fv framework residues of the human immunoglobulin are replaced with the corresponding non-human (e.g., murine) immunoglobulin residues. In some embodiments, a humanized antibody may contain residues not found in the recipient antibody or the donor antibody. These modifications may be made to further improve antibody performance. In some embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, wherein all or substantially all of the hypervariable loops (CDRs) correspond to those of a non-human (e.g., murine) immunoglobulin, and all or substantially all of the framework regions are those of a human immunoglobulin. A humanized antibody may also comprise at least a portion of the immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Humanized antibodies can be produced using molecular biology methods known in the art. Non-limiting examples of methods for producing humanized antibodies are described herein.
[0313] As used herein, the term "single-chain antibody" refers to a single polypeptide containing at least two immunoglobulin variable domains (e.g., the variable domains of mammalian immunoglobulin heavy or light chains) capable of specifically binding to an antigen. Non-limiting examples of single-chain antibodies are described herein.
[0314] As used herein, the term "multimeric antibody" refers to an antibody containing four or more (e.g., six, eight, or ten) immunoglobulin variable domains. In some embodiments, a multimeric antibody is capable of crosslinking one target molecule (e.g., CCR8) on the surface of a mammalian cell (e.g., Treg cells and cancer cells) to at least one second target molecule (e.g., PD-L1).
[0315] As used herein, the terms "subject" and "patient" are used interchangeably throughout the specification and refer to an animal (human or non-human) to which treatment is provided according to the methods of the invention. The present disclosure contemplates veterinary and non-veterinary applications. A human patient can be an adult or an adolescent (e.g., a person under 18 years of age). In addition to humans, patients include, but are not limited to, mice, rats, hamsters, guinea pigs, rabbits, ferrets, cats, dogs, and primates. This includes, for example, non-human primates (e.g., monkeys, chimpanzees, gorillas, etc.), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, pigs (e.g., pigs, minipigs), horses, dogs, cats, cattle, and other domestic, farm, and zoo animals.
[0316] As used herein, when referring to an antibody, the phrase "specifically binds" means that the antibody preferably interacts with its target molecule (e.g., CCR8) as compared to other molecules, because the interaction depends on the presence of a specific structure (i.e., an antigenic determinant or epitope) on the target molecule; in other words, the reagent recognizes and binds to a molecule including the specific structure, rather than all molecules under normal circumstances. An antibody that specifically binds to a target molecule can be referred to as a target-specific antibody. For example, an antibody that specifically binds to the CCR8 molecule can be referred to as a CCR8-specific antibody or an anti-CCR8 antibody.
[0317] As used herein, the terms "polypeptide", "peptide", and "protein" are used interchangeably and refer to an amino acid polymer of any length composed of at least two amino acids.
[0318] As used herein, the terms "polynucleotide", "nucleic acid molecule", and "nucleic acid sequence" are used interchangeably herein and refer to a nucleotide polymer of any length composed of at least two nucleotides, and include but are not limited to DNA, RNA, DNA / RNA hybrids, and their modifications.
[0319] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials for this invention are described herein; other suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated herein by reference in their entirety. In case of conflict, the present specification (including definitions) shall prevail.
[0320] Other features and advantages of the present invention will be apparent from the following detailed description, the accompanying drawings, and the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0321] Figure 1 Shows the effect of an anti-CCR8 antibody on in vivo tumor growth in a colon cancer model.
[0322] Figures 2A to 2C Shows the CDR sequences corresponding to anti-human CCR8 monoclonal antibodies 11B12, 11F5, and 11F8 and anti-human CCR8 monoclonal antibodies with CDR modifications as defined by the Kabat definition.
[0323] Figures 3A to 3C Shows the CDR sequences corresponding to anti-human CCR8 monoclonal antibodies 11B12, 11F5, and 11F8 and anti-human CCR8 monoclonal antibodies with CDR modifications as defined by the Chothia definition.
[0324] Figure 4 Shows some relevant amino acid sequences discussed in the present disclosure.
[0325] Figure 5 Shows some VH and VL combinations in the present disclosure.
[0326] Figure 6 Shows the average tumor volumes of each group of B-hPD-1 / hPD-L1 / hCCR8 mice that received subcutaneous injection of MC38 cells (murine colon cancer cells) and were treated with PBS (G1), Pembrolizumab analogue (G2), anti-CCR8 antibody 11F5 (G3), or a combination of Pembrolizumab analogue and 11F5 (G4).
[0327] Figure 7 Shows the average tumor volumes of each group of B-hPD-1 / hPD-L1 / hCCR8 mice that received subcutaneous injection of MC38 cells and were treated with PBS (G1), Pembrolizumab analogue (G2), anti-CCR8 antibody 11F5-SI (G3), a combination of Pembrolizumab analogue and 11F5-SI (G4), anti-CCR8 antibody 11B12-SI (G5), or a combination of Pembrolizumab analogue and 11B12-SI (G6).
[0328] Figure 8 Shows the blocking effect of anti-CCR8 antibody 11F5 and the antibody with CDR3 modification of 11F5 on the binding of hCCL1 to hCCR8 as determined by a calcium (Ca) ion flux experiment using human CCR8-expressing 293T cells. Detailed implementation
[0329] Chemokines and chemokine receptors play important roles in the immune defense system by controlling the migration, activation, differentiation, and survival of leukocytes. Based on the number and spacing of conserved cysteine residues in the N-terminal region, 50 human chemokines are classified into C, CC, CXC, and CX3C classes. Chemokine receptors belong to family A of G protein-coupled receptors (GPCRs), characterized by having a seven-transmembrane (7TM) helical domain. There are currently 18 human chemokine receptors, mainly activated by different subfamilies of chemokines: C (XCR1), CC (CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10), CXC (CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6), or CX3C (CX3CR1) and four atypical decoy chemokine receptors (ACKR: ACKR1, ACKR2, ACKR3 / CXCR7, and ACKR4). Chemokine receptors are thought to interact with their chemokine ligands through a two-step binding mechanism, in which: (i) the structured C-terminal region of the chemokine first binds to the N-terminal region and extracellular loop (ECL) of the receptor (chemokine recognition site 1, CRS1), allowing (ii) the unstructured N-terminal of the chemokine to target the 7TM helical bundle (chemokine recognition site 2, CRS2) and stabilize the receptor in an active conformation that promotes intracellular signal transduction via, for example, G-proteins or arrestins. Because of their key role in cell migration, chemokine receptors have become important therapeutic targets for inflammatory diseases and cancer.
[0330] Chemokine (C-C motif) receptor 8 (CCR8 or CDw198) is a seven-transmembrane G protein-coupled receptor (GPCR) belonging to the C-C subfamily of chemokine receptors. CCR8 is one of the most important chemokine receptors, mainly expressed in Tregs, with low expression in T helper cells 2 and monocytes. CCR8 is known to have four ligands: CCL1, CCL8, CCL16, and CCL18. Human CCL1 is the main ligand of human CCR8, which binds to both extracellular loop 2 and the N-terminal domain of the receptor. Specifically, CCL1 enhances the immunosuppressive activity of Tregs by recruiting CCR8, FOXp3, and IL-10, and it is a positive feedback mechanism. There are also reports that CCR8 is associated with poor prognosis in non-small cell lung cancer and colorectal cancer.
[0331] In multiple solid tumors, CCR8 is selectively upregulated in tumor-resident Treg cells, but is rare in Treg cells in peripheral blood mononuclear cells (PBMCs) or normal organs. Treg cells are immunosuppressive and generally inhibit or downregulate the induction and proliferation of effector T cells. These cells play an important role in maintaining self-tolerance and immune homeostasis. Tumor-resident Treg cells can inhibit anti-tumor immunity in the tumor microenvironment. High CCR8 expression is generally associated with shorter survival in cancer patients. Thus, CCR8 is a potential target for Treg cells. Inhibiting and / or depleting Treg cells by targeting CCR8 has several advantages. First, the expression of CCR8 is more restricted to Treg cells rather than CD8 T cells, without attenuation of anti-tumor activity of effector T cells. Second, systemic depletion of Treg cells usually leads to autoimmunity. Since CCR8 is rarely expressed on Treg cells in peripheral blood mononuclear cells (PBMCs) or normal organs, the risk of autoimmunity is low. Indeed, in a mouse model of colorectal tumors, treatment with a rat anti-mouse CCR8 blocking antibody produced significant anti-tumor activity and improved long-term survival. Thus, due to its highly selective expression in tumor-resident Treg cells, CCR8 is an excellent target among various known Treg targets. Anti-CCR8 antibodies can also have single-agent activity in a PD-1-resistant background and can restore PD-1 activity when used as a combination partner.
[0332] A detailed description of CCR8 and its functions can be found, for example, in Plitas G. et al., "Regulatory T cells exhibit distinct features in human breast cancer", Immunity 45.5 (2016): 1122-1134; Villarreal et al., "Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer", Cancer research 78.18 (2018): 5340-5348; Arimont et al., "Structural analysis of chemokine receptor-ligand interactions", Journal of Medicinal Chemistry 60.12 (2017): 4735-4779; Li et al., "Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors", World Journal of Gastroenterology 26.31 (2020): 4656. The full texts of the above documents are incorporated herein by reference in their entirety.
[0333] The present disclosure provides anti-CCR8 antibodies, antigen-binding fragments thereof, and methods of using these anti-CCR8 antibodies and antigen-binding fragments to inhibit tumor growth and treat cancer. Specifically, the present disclosure provides fully human anti-CCR8 antibodies (e.g., produced by mice having humanized heavy-chain immunoglobulin loci and humanized light-chain immunoglobulin loci). Anti-CCR8 antibodies and antigen-binding fragments
[0334] The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to CCR8. The antibodies and antigen-binding fragments described herein are capable of binding to CCR8. In some embodiments, these antibodies can block the binding of CCL1 to CCR8, thereby inhibiting the inhibitory function of CCL1-induced tumor-resident Treg cells. In some embodiments, these antibodies can inhibit CCL1-CCR8-mediated downstream signaling. In some embodiments, these antibodies can elicit complement-dependent cytotoxicity (CMC) or antibody-dependent cell cytotoxicity (ADCC). In some embodiments, these antibodies and their antigen-binding fragments can block the interaction between CCR8 and CCR8 ligands (such as CCL1, CCL8, CCL16, or CCL18).
[0335] The present disclosure provides, for example, murine anti-CCR8 antibodies 11B12, 11F5, and 11F8, their chimeric antibodies, and their humanized antibodies.
[0336] The CDR sequences of 11B12 and 11B12-derived antibodies (such as humanized antibodies) include the CDRs of the heavy chain variable domain (SEQ ID NOs: 1, 2, 3) and the CDRs of the light chain variable domain (SEQ ID NOs: 19, 20, 21) as defined by the Kabat definition. The CDRs can also be defined by the Chothia definition. According to the Chothia definition, the CDR sequences of the heavy chain variable domain are shown as SEQ ID NOs: 10, 11, 12, and the CDR sequences of the light chain variable domain are shown as SEQ ID NOs: 28, 29, 30.
[0337] Similarly, the CDR sequences of 11F5 and 11F5-derived antibodies include the CDRs of the heavy chain variable domain (SEQ ID NOs: 4, 5, 6) and the CDRs of the light chain variable domain (SEQ ID NOs: 22, 23, 24) as defined by the Kabat definition. According to the Chothia definition, the CDR sequences of the heavy chain variable domain are shown as SEQ ID NOs: 13, 14, 15, and the CDRs of the light chain variable domain are shown as SEQ ID NOs: 31, 32, 33.
[0338] Similarly, the CDR sequences of 11F8 and 11F8-derived antibodies include the CDRs of the heavy chain variable domain (SEQ ID NOs: 7, 8, 9) and the CDRs of the light chain variable domain (SEQ ID NOs: 25, 26, 27) as defined by the Kabat definition. According to the Chothia definition, the CDR sequences of the heavy chain variable domain are shown as SEQ ID NOs: 16, 17, 18, and the CDRs of the light chain variable domain are shown as SEQ ID NOs: 34, 35, 36.
[0339] The amino acid sequence of the heavy chain variable region of the 11B12 antibody is shown in SEQ ID NO: 37. The amino acid sequence of the light chain variable region of the 11B12 antibody is shown in SEQ ID NO: 40. The amino acid sequence of the heavy chain variable region of the 11F5 antibody is shown in SEQ ID NO: 38. The amino acid sequence of the light chain variable region of the 11F5 antibody is shown in SEQ ID NO: 41. The amino acid sequence of the heavy chain variable region of the 11F8 antibody is shown in SEQ ID NO: 39. The amino acid sequence of the light chain variable region of the 11F8 antibody is shown in SEQ ID NO: 42.
[0340] Also provided are the amino acid sequences of the heavy chain variable region and the light chain variable region of the humanized antibody. Since the methods for humanizing murine antibodies can vary (e.g., sequences can be modified by substitution with different amino acids), the heavy and light chains of the antibody can have more than one version of the humanized sequence. In some embodiments, the humanized heavy chain variable region has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 37, 38, or 39. In some embodiments, the humanized light chain variable region has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 40, 41, or 42. The heavy chain variable region sequence can be paired with the corresponding light chain variable region sequence, and together they bind CCR8.
[0341] The percent humanization refers to the percent identity of the heavy or light chain variable region sequence compared to human antibody sequences in the International Immunogenetics Information System (IMGT) database. A top hit means that the heavy or light chain variable region sequence is closer to a particular species than to other species. For example, a best match to human means that the sequence is closer to human than to other species. A top hit to both human and cynomolgus monkey (Macaca fascicularis) means that the sequence has the same percent identity to human and cynomolgus monkey sequences and that these percent identities are the highest compared to sequences of other species. In some embodiments, the percent humanization is greater than 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%. Detailed descriptions of how to determine percent humanization and how to determine a top hit are known in the art and are described, for example, in Jones et al., “The INNs and outs of antibody nonproprietary names”, MAbs. Vol. 8, No. 1, Taylor & Francis, 2016, which is incorporated herein by reference in its entirety. High percent humanization generally has various advantages, such as being safer and more effective in the human body, having a greater likelihood of being tolerated by human subjects, and / or having a lower likelihood of side effects. In some embodiments, the antibody is a fully human antibody.
[0342] In addition, in some embodiments, the antibody or antigen-binding fragment thereof described herein may further comprise one, two, or three heavy chain variable region CDRs selected from: SEQ ID NO: 1-3, SEQ ID NO: 4-6, SEQ ID NO: 7-9, SEQ ID NO: 10-12, SEQ ID NO: 13-15, and SEQ ID NO: 16-18; and / or one, two, or three light chain variable region CDRs selected from: SEQ ID NO: 19-21, SEQ ID NO: 22-24, SEQ ID NO: 25-27, SEQ ID NO: 28-30, SEQ ID NO: 31-33, and SEQ ID NO: 34-36.
[0343] In some embodiments, the antibody may have a heavy chain variable region (VH) comprising complementarity determining regions (CDR) 1, 2, 3, wherein the CDR1 region comprises or consists of an amino acid sequence having at least 80%, 85%, 90% or 95% identity to a selected VH CDR1 amino acid sequence, the CDR2 region comprises or consists of an amino acid sequence having at least 80%, 85%, 90% or 95% identity to a selected VH CDR2 amino acid sequence, and the CDR3 region comprises or consists of an amino acid sequence having at least 80%, 85%, 90% or 95% identity to a selected VH CDR3 amino acid sequence. In some embodiments, the antibody may have a light chain variable region (VL) comprising CDR1, 2, 3, wherein the CDR1 region comprises or consists of an amino acid sequence having at least 80%, 85%, 90% or 95% identity to a selected VL CDR1 amino acid sequence, the CDR2 region comprises or consists of an amino acid sequence having at least 80%, 85%, 90% or 95% identity to a selected VL CDR2 amino acid sequence, and the CDR3 region comprises or consists of an amino acid sequence having at least 80%, 85%, 90% or 95% identity to a selected VL CDR3 amino acid sequence. The selected VH CDR1, 2, 3 amino acid sequences and the selected VL CDR1, 2, 3 amino acid sequences are as shown in Figures 2A to 2C (Kabat CDR) and Figures 3A to 3C (Chothia CDR).
[0344] In some embodiments, the present disclosure relates to CDR-modified VH or VL. In some embodiments, the "DG" in VH CDR2 of the antibody described herein is mutated to "SG", "AG" or "DA" to produce a CDR-modified VH. For example, in one embodiment, the "DG" in VH CDR2 of 11B12 is mutated to "SG", and the resulting CDR-modified VH is named 11B12-SG VH. The sequences of a portion of such CDR-modified VH can be found in Figure 4 .
[0345] In some embodiments, the "DG" in VL CDR1 of the antibody described herein is mutated to "SG", "AG" or "DA" to produce a CDR-modified VL. For example, in one embodiment, the "DG" in VL CDR1 of 11B12 is mutated to SG, and the resulting CDR-modified VL is named 11B12-SG VL. The sequences of a portion of such CDR-modified VL can be found in Figure 4 .
[0346] In some embodiments, the present disclosure relates to framework region-modified (FR-modified) VH. In some embodiments, the "DNS" in the VH framework of the antibodies described herein is mutated to "DNA" to generate FR-modified VH. For example, in one embodiment, the "DNS" in the VH framework of 11B12 is mutated to "DNA", and the resulting FR-modified VH is named 11B12-DNA VH. The sequences of a portion of such FR-modified VH can be found in Figure 4 (e.g., SEQ ID NO: 69-71). Thus, in some embodiments, the antibody has an S74A mutation (Kabat numbering). In some embodiments, the amino acid at position 74 (Kabat numbering) is A.
[0347] In some embodiments, the VH has both FR modification (e.g., DNA) and CDR modification (e.g., SG). In one embodiment, the "DNS" in the VH framework of 11B12 is mutated to "DNA", and the "DG" in the VH CDR2 of 11B12 is mutated to "SG", and the resulting FR-modified and CDR-modified VH is named 11B12-SG-DNA VH.
[0348] In some embodiments, CDR3-modified VH of 11F5 can be generated. In some embodiments, the amino acid "N" at position 3 in the VH CDR3 of 11F5 (e.g., SEQ ID NO: 6 or 15) is mutated to "S". In some embodiments, the amino acid "Y" at position 5 in the VH CDR3 of 11F5 (e.g., SEQ ID NO: 6 or 15) is mutated to "V". In some embodiments, the amino acid "Y" at position 6 in the VH CDR3 of 11F5 (e.g., SEQ ID NO: 6 or 15) is mutated to "N". For example, the amino acid "N" at position 3 in the VH CDR3 of 11F5 can be mutated to "S", and the resulting CDR-modified VH is named 11F5-N3S VH; the amino acid "Y" at position 5 in the VH CDR3 of 11F5 can be mutated to "V", and the resulting CDR-modified VH is named 11F5-Y5V VH; the amino acid "Y" at position 6 in the VH CDR3 of 11F5 can be mutated to "N", and the resulting CDR-modified VH is named 11F5-Y6N VH; the amino acid "N" at position 3 and the amino acid "Y" at position 5 in the VH CDR3 of 11F5 can be mutated to "S" and "V" respectively, and the resulting CDR-modified VH is named 11F5-N3S-Y5V VH; the amino acid "N" at position 3 and the amino acid "Y" at position 6 in the VH CDR3 of 11F5 can be mutated to "S" and "N" respectively, and the resulting CDR-modified VH is named 11F5-N3S-Y6N VH; the amino acid "Y" at position 5 and the amino acid "Y" at position 6 in the VH CDR3 of 11F5 can be mutated to "V" and "N" respectively, and the resulting CDR-modified VH is named 11F5-Y5V-Y6N VH; in the VH CDR3 of 11F5, the amino acid "N" at position 3, the amino acid "Y" at position 5 and the amino acid "Y" at position 6 can be mutated to "S", "V" and "N" respectively, and the resulting CDR-modified VH is named 11F5-N3S-Y5V-Y6N VH. The sequences of these CDR-modified VH can be found in Figure 4 .
[0349] In some embodiments, the VH of any antibody described herein can be paired with the VL of any antibody described herein to form an antibody. For example, in one embodiment, the VH of 11B12 is paired with the VL of 11F8, and the resulting antibody is named 11B12-11F8. In one embodiment, the VH of 11B12-SG is paired with the VL of 11F8-SG, and the resulting antibody is named 11B12-SG-11F8-SG. In one embodiment, the VH of 11B12-SG is paired with the VL of 11B12-SG, and the resulting antibody is named 11B12-SG-11B12-SG. The binding affinities of a portion of such antibodies are shown in Tables 15, 16, and 19.Figure 5 lists some publicly available VH and VL combinations. As Figure 5 shown, at least 163 VH and VL combinations are publicly available. In addition, the VH CDRs and VL CDRs in VH and VL can also be combined, as Figure 5 shown.
[0350] In one aspect, the present disclosure relates to an antibody or an antigen-binding fragment thereof that binds to CCR8 (chemokine (C-C motif) receptor 8), the antibody or antigen-binding fragment thereof comprising:
[0351] a heavy-chain variable region (VH) comprising complementarity-determining regions (CDR) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR3 amino acid sequence; and
[0352] a light-chain variable region (VL) comprising CDR1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR3 amino acid sequence,
[0353] wherein the selected VH CDR1, 2, and 3 amino acid sequences are one of the following:
[0354] (1) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:1, 2, and 3, respectively;
[0355] (2) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:4, 5, and 6, respectively;
[0356] (3) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:7, 8, and 9, respectively;
[0357] (4) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:10, 11, and 12, respectively;
[0358] (5) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:13, 14, and 15, respectively;
[0359] (6) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:16, 17, and 18, respectively;
[0360] (7) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:72, 73, and 74, respectively;
[0361] (8) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:75, 76, and 77, respectively;
[0362] (9) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:78, 79, and 80, respectively;
[0363] (10) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:81, 82, and 83, respectively;
[0364] (11) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:84, 85, and 86, respectively;
[0365] (12) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:87, 88, and 89, respectively;
[0366] (13) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:90, 91, and 92, respectively;
[0367] (14) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:93, 94, and 95, respectively;
[0368] (15) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 96, 97, and 98, respectively;
[0369] (16) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 99, 100, and 101, respectively;
[0370] (17) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 102, 103, and 104, respectively;
[0371] (18) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 105, 106, and 107, respectively;
[0372] (19) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 144, 145, and 146, respectively;
[0373] (20) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 147, 148, and 149, respectively;
[0374] (21) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 150, 151, and 152, respectively;
[0375] (22) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 153, 154, and 155, respectively;
[0376] (23) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 156, 157, and 158, respectively;
[0377] (24) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 159, 160, and 161, respectively;
[0378] (25) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 162, 163, and 164, respectively;
[0379] (26) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 165, 166, and 167, respectively;
[0380] (27) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 168, 169, and 170, respectively;
[0381] (28) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 171, 172, and 173 respectively;
[0382] (29) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 174, 175, and 176 respectively;
[0383] (30) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 177, 178, and 179 respectively;
[0384] (31) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 219, 220, and 221 respectively;
[0385] (32) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 222, 223, and 224 respectively;
[0386] (33) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 225, 226, and 227 respectively;
[0387] (34) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 228, 229, and 230 respectively;
[0388] (35) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 231, 232, and 233 respectively;
[0389] (36) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 234, 235, and 236 respectively;
[0390] (37) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 237, 238, and 239 respectively;
[0391] (38) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 240, 241, and 242 respectively;
[0392] (39) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 243, 244, and 245 respectively;
[0393] (40) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 246, 247, and 248 respectively;
[0394] (41) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 249, 250, and 251, respectively;
[0395] (42) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 252, 253, and 254, respectively;
[0396] (43) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 255, 256, and 257, respectively; and
[0397] (44) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 258, 259, and 260, respectively;
[0398] wherein the selected VL CDR1, 2, and 3 amino acid sequences are one of the following:
[0399] (1) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 19, 20, and 21, respectively;
[0400] (2) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 22, 23, and 24, respectively;
[0401] (3) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 25, 26, and 27, respectively;
[0402] (4) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 28, 29, and 30, respectively;
[0403] (5) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 31, 32, and 33, respectively;
[0404] (6) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 34, 35, and 36, respectively;
[0405] (7) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 108, 109, and 110, respectively;
[0406] (8) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 111, 112, and 113, respectively;
[0407] (9) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 114, 115, and 116, respectively;
[0408] (10) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 117, 118, and 119, respectively;
[0409] (11) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 120, 121, and 122, respectively;
[0410] (12) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 123, 124, and 125, respectively;
[0411] (13) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 126, 127, and 128, respectively;
[0412] (14) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 129, 130, and 131, respectively;
[0413] (15) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 132, 133, and 134, respectively;
[0414] (16) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 135, 136, and 137, respectively;
[0415] (17) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 138, 139, and 140, respectively;
[0416] (18) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 141, 142, and 143, respectively;
[0417] (19) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 180, 181, and 182, respectively;
[0418] (20) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 183, 184, and 185, respectively;
[0419] (21) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 186, 187, and 188, respectively;
[0420] (22) The selected VL CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 189, 190, and 191, respectively;
[0421] (23) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 192, 193, and 194, respectively;
[0422] (24) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 195, 196, and 197, respectively;
[0423] (25) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 198, 199, and 200, respectively;
[0424] (26) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 201, 202, and 203, respectively;
[0425] (27) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 204, 205, and 206, respectively;
[0426] (28) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 207, 208, and 209, respectively;
[0427] (29) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 210, 211, and 212, respectively; and
[0428] (30) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 213, 214, and 215, respectively.
[0429] In one aspect, the present disclosure relates to an antibody or an antigen-binding fragment thereof that binds to CCR8 (chemokine (C-C motif) receptor 8), the antibody or antigen-binding fragment thereof comprising:
[0430] A heavy chain variable region (VH) comprising complementarity-determining regions (CDR) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR3 amino acid sequence; and
[0431] The variable light chain region (VL) including CDR1, 2, and 3, wherein the VL CDR1 region includes an amino acid sequence having at least 80% identity with a selected VL CDR1 amino acid sequence, the VL CDR2 region includes an amino acid sequence having at least 80% identity with a selected VL CDR2 amino acid sequence, and the VL CDR3 region includes an amino acid sequence having at least 80% identity with a selected VL CDR3 amino acid sequence,
[0432] wherein the selected VH CDR1, 2, and 3 amino acid sequences are one of the following:
[0433] (1) The selected VH CDR1 is SYVMH (SEQ ID NO:99); the selected VH CDR2 is VISYX 1 X 2 SDKYYADSVKG (SEQ ID NO:100); the selected VH CDR3 is
[0434] GRGYRYGQSYYYGMDV (SEQ ID NO:101);
[0435] (2) The selected VH CDR1 is SYVVH (SEQ ID NO:102); the selected VH CDR2 is VISYX 1 X 2 DNKFYADSVKG (SEQ ID NO:103); the selected VH CDR3 is
[0436] GRX 5 YX 6 X 7 YYGLDV (SEQ ID NO:104);
[0437] (3) The selected VH CDR1 is TYVMH (SEQ ID NO:105); the selected VH CDR2 is VISYX 1 X 2 NNKYYADSVKG (SEQ ID NO:106); the selected VH CDR3 is GRSYVNYYGLDV (SEQ ID NO:107);
[0438] (4) The selected VH CDR1 is GFSFSSY (SEQ ID NO:171); the selected VH CDR2 is SYX 1 X 2 SD(SEQID NO:172); the selected VH CDR3 is GRGYRYGQSYYYGMDV (SEQ ID NO:173);
[0439] (5) The selected VH CDR1 is GFTFSSY (SEQ ID NO:174); the selected VH CDR2 is SYX 1 X 2 DN (SEQID NO:175); the selected VH CDR3 is GRX 5 YX 6 X 7 YYGLDV (SEQ ID NO:176); and
[0440] (6) The selected VH CDR1 is GFTFSTY (SEQ ID NO:177); the selected VH CDR2 is SYX 1 X 2 NN (SEQID NO:178); the selected VH CDR3 is GRSYVNYYGLDV (SEQ ID NO:179);
[0441] wherein the selected VL CDR1, 2, and 3 amino acid sequences are one of the following:
[0442] (1) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:135); the selected VL CDR2 is EVSNRFS (SEQ ID NO:136); the selected VL CDR3 is MQSIKLPLT (SEQ ID NO:137);
[0443] (2) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:138); the selected VL CDR2 is EVSNRFS (SEQ ID NO:139); the selected VL CDR3 is MQSLKVPPT (SEQ ID NO:140);
[0444] (3) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:141); the selected VL CDR2 is EVSNRFS (SEQ ID NO:142); the selected VL CDR3 is MQSVKIPLT (SEQ ID NO:143);
[0445] (4) The selected VL CDR1 is KSSQSLLYSX 3 X 4KTYLY (SEQ ID NO:207); the selected VL CDR2 is EVSNRFS (SEQ ID NO:208); the selected VL CDR3 is MQSIKLPLT (SEQ ID NO:209);
[0446] (5) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:210); the selected VL CDR2 is EVSNRFS (SEQ ID NO:211); the selected VL CDR3 is MQSLKVPPT (SEQ ID NO:212); and
[0447] (6) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:213); the selected VL CDR2 is EVSNRFS (SEQ ID NO:214); the selected VL CDR3 is MQSVKIPLT (SEQ ID NO:215);
[0448] wherein X in each sequence 1 and X 3 are independently selected from the group consisting of D, S, and A,
[0449] wherein X in each sequence 2 and X 4 are independently selected from the group consisting of G and A,
[0450] wherein X in SEQ ID NO:104 or 176 5 is independently selected from the group consisting of N and S,
[0451] wherein X in SEQ ID NO:104 or 176 6 is independently selected from the group consisting of Y and V,
[0452] wherein X in SEQ ID NO:104 or 176 7 is independently selected from the group consisting of Y and N.
[0453] In some embodiments, humanization may involve limited modification of the CDRs. However, these modifications will have a limited impact on binding affinity. In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a heavy-chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:1 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:2 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:3 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0454] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a light-chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:19 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:20 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:21 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0455] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a heavy-chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:4 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:5 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:6 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0456] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a light-chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:22 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:23 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:24 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0457] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a heavy-chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:7 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:8 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:9 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0458] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a light chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:25 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:26 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:27 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0459] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:10 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:11 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:12 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0460] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a light chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:28 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:29 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:30 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0461] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:13 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:14 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:15 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0462] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a light chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:31 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:32 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:33 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0463] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:16 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:17 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:18 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0464] In some embodiments, the antibodies or antigen-binding fragments described herein may comprise a light chain variable domain containing one, two, or three of the following CDRs: the CDR of SEQ ID NO:34 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:35 with zero, one, or two amino acid insertions, deletions, or substitutions; the CDR of SEQ ID NO:36 with zero, one, or two amino acid insertions, deletions, or substitutions.
[0465] Insertions, deletions, and substitutions may be within the CDR sequence or at one or both ends of the CDR sequence. In some embodiments, the CDRs are determined based on the Kabat definition. In some embodiments, the CDRs are determined based on the Chothia definition.
[0466] In some embodiments, there are no more than one insertion, deletion, or substitution. In some embodiments, there are no more than two insertions, deletions, or substitutions. In some embodiments, there are no more than three insertions, deletions, or substitutions. In some embodiments, there are no more than four insertions, deletions, or substitutions. In some embodiments, VH has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the sequences of SEQ ID NO:37 - 39, 63 - 65, 69 - 71, 216, and 261 - 267. In some embodiments, VL has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the sequences of SEQ ID NO:40 - 42 and 66 - 68.
[0467] The present disclosure also provides an antibody or an antigen-binding fragment thereof that binds to CCR8. The antibody or its antigen-binding fragment comprises: a heavy chain variable region (VH) comprising or consisting of an amino acid sequence having at least 80%, 85%, 90% or 95% identity to a selected VH sequence; and a light chain variable region (VL) comprising or consisting of an amino acid sequence having at least 80%, 85%, 90% or 95% identity to a selected VL sequence. In some embodiments, the selected VH sequence is SEQ ID NO:37 and the selected VL sequence is SEQ ID NO:40. In some embodiments, the selected VH sequence is SEQ ID NO:38 and the selected VL sequence is SEQ ID NO:41. In some embodiments, the selected VH sequence is SEQ ID NO:39 and the selected VL sequence is SEQ ID NO:42. In some embodiments, the selected VH sequence is SEQ ID NO:261 and the selected VL sequence is SEQ ID NO:41. In some embodiments, the selected VH sequence is SEQ ID NO:262 and the selected VL sequence is SEQ ID NO:41. In some embodiments, the selected VH sequence is SEQ ID NO:263 and the selected VL sequence is SEQ ID NO:41. In some embodiments, the selected VH sequence is SEQ ID NO:264 and the selected VL sequence is SEQ ID NO:41. In some embodiments, the selected VH sequence is SEQ ID NO:265 and the selected VL sequence is SEQ ID NO:41. In some embodiments, the selected VH sequence is SEQ ID NO:266 and the selected VL sequence is SEQ ID NO:41. In some embodiments, the selected VH sequence is SEQ ID NO:267 and the selected VL sequence is SEQ ID NO:41.
[0468] To determine the percent identity between two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). Then the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps that need to be introduced to achieve optimal alignment of the two sequences and the length of each gap. For illustrative purposes, the comparison of sequences and the determination of the percent identity between two sequences can be accomplished using the Blossum 62 scoring matrix, where the gap penalty is 12, the gap extension penalty is 4, and the frameshift gap penalty is 5.
[0469] The present disclosure also provides a nucleic acid comprising a polynucleotide encoding a polypeptide that comprises an immunoglobulin heavy chain or an immunoglobulin light chain. The immunoglobulin heavy chain or immunoglobulin light chain comprises a CDR as shown in Figures 2A to 2C or Figures 3A to 3C or has a sequence as shown in Figure 4 When the polypeptide pairs with a corresponding polypeptide (e.g., a corresponding heavy chain variable region or a corresponding light chain variable region), the paired polypeptides bind CCR8 (e.g., human CCR8).
[0470] Anti-CCR8 antibodies and antigen-binding fragments can also be antibody variants (including derivatives and conjugates) of antibodies or antibody fragments and multispecific (e.g., bispecific) antibodies or antibody fragments. Other antibodies provided herein are polyclonal antibodies, monoclonal antibodies, multispecific (multimeric, e.g., bispecific) antibodies, human antibodies, chimeric antibodies (e.g., human-mouse chimeras), single-chain antibodies, intracellularly produced antibodies (i.e., intrabodies), and antigen-binding fragments thereof. The antibody or its antigen-binding fragment can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. In some embodiments, the antibody or its antigen-binding fragment is an IgG antibody or its antigen-binding fragment.
[0471] Antibody fragments are suitable for the provided methods so long as they retain the desired affinity and specificity of the full-length antibody. Thus, an antibody fragment that binds CCR8 will retain the ability to bind CCR8. An Fv fragment is an antibody fragment that contains the complete antigen recognition and binding site. This region consists of a dimer of one heavy-chain variable domain and one light-chain variable domain that are tightly associated, which association can be of a covalent nature, such as in a scFv. In this configuration, it is the interaction of the three CDRs of each variable domain that defines the antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs, or subsets thereof, confer antigen-binding specificity to the antibody. However, even a single variable domain (or half an Fv containing only the three CDRs specific for a particular antigen) has the ability to recognize and bind an antigen, although the affinity is generally lower than that of the entire binding site. A single-chain Fv (scFv) antibody fragment comprises the VH and VL domains (or regions) of an antibody, wherein these domains are present in a single polypeptide chain. Typically, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains such that the scFv forms the desired structure for antigen binding. In some embodiments, the polypeptide comprises a linker having a sequence of GGGS (SEQ ID NO:61) or GGGSGGGS (SEQ ID NO:62).
[0472] The present disclosure also provides antibodies or antigen-binding fragments thereof that cross-compete with any antibody or antigen-binding fragment described herein. Cross-competition assays are known in the art and are described, for example, in Moore et al., “Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.”, Journal of virology 70.3 (1996):1863 - 1872, the entire text of which is incorporated herein by reference. In one aspect, the present disclosure also provides antibodies or antigen-binding fragments thereof that bind the same epitope or region as any antibody or antigen-binding fragment described herein. Epitope binning assays are known in the art and are described, for example, in Estep et al., “High throughput solution-based measurement of antibody-antigen affinity and epitope binning.”, MAbs. Vol.5. No.2. Taylor & Francis, 2013, the entire text of which is incorporated herein by reference.
[0473] Antibodies and antigen-binding fragments
[0474] The present disclosure provides various antibodies and antigen-binding fragments thereof derived from the anti-CCR8 antibodies described herein. Generally, an antibody (also referred to as an immunoglobulin) consists of two types of polypeptide chains, namely, a light chain and a heavy chain. Non-limiting examples of the antibodies of the present disclosure can be intact four-immunoglobulin chain antibodies comprising two heavy chains and two light chains. The heavy chain of the antibody can be of any isotype (including IgM, IgG, IgE, IgA, or IgD) or sub-isotype (including IgG1, IgG2, IgG2a, IgG2b, IgG3, IgG4, IgE1, IgE2, etc.). The light chain can be a κ light chain or a λ light chain. The antibody can include two identical copies of the light chain and two identical copies of the heavy chain. The heavy chains, each containing a variable domain (or variable region, V H ) and multiple constant domains (or constant regions), are bound to each other through disulfide bonds within their constant domains to form the "backbone" of the antibody. The light chains, each containing a variable domain (or variable region, V L ) and a constant domain (or constant region), are bound to one heavy chain through disulfide bonds, respectively. The variable region of each light chain is aligned with the variable region of the heavy chain to which it binds. The variable regions of the light and heavy chains each contain three hypervariable regions that are sandwiched between more conserved framework regions (FRs).
[0475] These hypervariable regions (termed complementarity-determining regions (CDRs)) form loops that comprise the antigen-binding surface of the antibody. Most of the four framework regions adopt a β-sheet conformation, while the CDRs form loops that connect the β-sheet structures and in some cases are part of the β-sheet structures. The CDRs in each chain are held tightly together by the framework regions and, together with the CDRs from the other chain, contribute to the formation of the antigen-binding region.
[0476] Methods for identifying the CDR regions of an antibody by analyzing the amino acid sequence of the antibody are well known and typically use many definitions of CDRs. The Kabat definition is based on sequence variability, and the Chothia definition is based on the position of structural loop regions. These methods and definitions are described, for example, in Martin, “Protein sequence and structure analysis of antibody variable domains", Antibody engineering, Springer Berlin Heidelberg, 2001. 422 - 439; Abhinandan et al., “Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains", Molecular immunology 45.14 (2008): 3832 - 3839; Wu, T.T. and Kabat, E.A. (1970) J. Exp. Med. 132: 211 - 250; Martin et al., Methods Enzymol. 203: 121 - 53 (1991); Morea et al., Biophys Chem. 68(1 - 3): 9 - 16 (Oct. 1997); Morea et al., J Mol Biol. 275(2): 269 - 94 (Jan. 1998); Chothia et al., Nature 342(6252): 877 - 83 (Dec. 1989); Ponomarenko and Bourne, BMC Structural Biology 7: 64 (2007), the entire texts of each of the above - mentioned documents are incorporated herein by reference.
[0477] CDRs are very important for recognizing epitopes of antigens. As used herein, an “epitope” is the smallest portion of a target molecule that can be specifically bound by the antigen - binding domain of an antibody. The minimum size of an epitope can be about three, four, five, six, or seven amino acids, but these amino acids need not be in a continuous linear sequence in the primary structure of the antigen, since the epitope can depend on the three - dimensional conformation of the antigen based on its secondary and tertiary structures.
[0478] In some embodiments, the antibody is a full immunoglobulin molecule (e.g., IgG1, IgG2a, IgG2b, IgG3, IgM, IgD, IgE, IgA). The IgG subclasses (IgG1, IgG2, IgG3, and IgG4) are highly conserved, but their constant regions differ, particularly in the hinge and upper CH2 domains. The sequences and differences of the IgG subclasses are known in the art and are described, for example, in Vidarsson et al., "IgG subclasses and allotypes: from structure to effector functions", Frontiers in immunology 5 (2014); Irani et al., "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases", Molecular immunology 67.2 (2015): 171-182; Shakib, Farouk editors, "The human IgG subclasses: molecular analysis of structure, function and regulation.", Elsevier, 2016, each of which is incorporated herein by reference in its entirety.
[0479] The antibody can also be an immunoglobulin molecule derived from any species (e.g., human, rodent, mouse, camelid). The antibodies disclosed herein also include, but are not limited to, polyclonal antibodies, monoclonal antibodies, monospecific antibodies, multispecific antibodies, and chimeric antibodies comprising an immunoglobulin binding domain fused to another polypeptide. The term "antigen-binding domain" or "antigen-binding fragment" is a part of the antibody that retains the specific binding activity of the full antibody, i.e., any part of the antibody that is capable of specifically binding to an epitope on the target molecule of the full antibody. It includes, for example, Fab, Fab', F(ab') 2and variants of these fragments. Thus, in some embodiments, the antibody or antigen-binding fragment thereof can be, for example, scFv, Fv, Fd, dAb, bispecific antibody, bispecific scFv, diabody, linear antibody, single-chain antibody molecule, multispecific antibody formed from antibody fragments, and any polypeptide comprising an antibody-binding domain or a binding domain homologous thereto. Non-limiting examples of antigen-binding domains include, for example, the heavy-chain and / or light-chain CDRs of a full antibody, the heavy-chain and / or light-chain variable regions of a full antibody, the full-length heavy or light chain of a full antibody, or a single CDR from a full antibody heavy or light chain.
[0480] Antibody fragments suitable for the methods described herein are also provided. A Fab fragment contains the variable and constant domains of the light chain and the variable domain and the first constant domain (CH1) of the heavy chain. F(ab') 2 The antibody fragment contains a pair of Fab fragments that are typically covalently linked near their carboxy termini by a hinge cysteine between them. Other chemical conjugations of antibody fragments are also known in the art.
[0481] A diabody is a small antibody fragment with two antigen-binding sites that contains VH and VL connected on the same polypeptide chain. By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains on the other chain and generate two antigen-binding sites.
[0482] A linear antibody comprises a pair of tandem Fd segments (VH-CH1-VH-CH1) that together with complementary light-chain polypeptides form a pair of antigen-binding regions. Linear antibodies can be bispecific or monospecific.
[0483] The antibodies and antibody fragments of the present disclosure can be modified in the Fc region to provide desired effector functions or serum half-life.
[0484] The multimerization of antibodies can be achieved by natural aggregation of the antibodies or by chemical or recombinant ligation techniques known in the art. For example, a certain percentage of a purified antibody preparation (e.g., purified IgG 1 molecules) spontaneously forms protein aggregates containing antibody homodimers and other higher-order antibody multimers.
[0485] Alternatively, antibody homodimers can be formed by chemical ligation techniques known in the art. For example, heterobifunctional crosslinking agents including but not limited to SMCC (succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate) and SATA (N-succinimidyl S-acetylthioacetate) can be used to form antibody multimers. An exemplary protocol for forming antibody homodimers is described in Ghetie et al. (Proc. Natl. Acad. Sci. U.S.A. 94:7509-7514, 1997). By pepsin digestion, antibody homodimers can be converted to Fab' 2 homodimers. Another method for forming antibody homodimers is by using the self-complementary T15 peptide, which is described in Zhao et al. (J. Immunol. 25:396-404, 2002).
[0486] In some embodiments, the multispecific antibody is a bispecific antibody. Bispecific antibodies can be prepared by engineering the interface between a pair of antibody molecules to maximize the percentage of heterodimers recovered from recombinant cell culture. For example, the interface can comprise at least a portion of the CH3 domain of the antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). By replacing the large amino acid side chains with smaller amino acid side chains (e.g., alanine or threonine), a compensatory "cavity" of the same or similar size as the large side chain is created at the interface of the second antibody molecule. This provides a mechanism by which the yield of heterodimers can be higher than other unwanted end products such as homodimers. This method is described, for example, in WO 96 / 27011, which is incorporated herein by reference in its entirety.
[0487] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one antibody in the heteroconjugate can be conjugated to avidin and another antibody can be conjugated to biotin. Heteroconjugate antibodies can also be prepared using any convenient cross-linking method. Suitable cross-linking agents and cross-linking techniques are well known in the art and are disclosed in U.S. Patent 4,676,980, which is incorporated herein by reference in its entirety.
[0488] Methods for generating bispecific antibodies from antibody fragments are also known in the art. For example, bispecific antibodies can be prepared using chemical ligation. Brennan et al. (Science 229:81, 1985) described a method in which intact antibodies were proteolytically cleaved to generate F(ab') 2Fragments. These fragments are reduced in the presence of the dithiol chelator sodium arsenite to stabilize adjacent dithiols and prevent intermolecular disulfide formation. The resulting Fab' fragments are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab' TNB derivatives is then converted to Fab' thiol by reduction with mercaptoethylamine and mixed with an equimolar amount of the other Fab' TNB derivative to form a bispecific antibody.
[0489] Any of the antibodies or antigen-binding fragments described herein can be conjugated to a stabilizing molecule (e.g., a molecule that increases the half-life of the antibody or its antigen-binding fragment in a subject or in solution). Non-limiting examples of stabilizing molecules include: polymers (e.g., polyethylene glycol) or proteins (e.g., serum albumin, such as human serum albumin). Conjugation of a stabilizing molecule can increase the half-life or extend the biological activity of an antibody or antigen-binding fragment in vitro (e.g., in tissue culture or when stored in a pharmaceutical composition) or in vivo (e.g., in a human body).
[0490] In some embodiments, the antibodies or antigen-binding fragments described herein can be conjugated to a therapeutic agent. Antibody-drug conjugates comprising an antibody or its antigen-binding fragment can be covalently or non-covalently bound to a therapeutic agent. In some embodiments, the therapeutic agent is a cytotoxic agent or a cell growth inhibitor (e.g., cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, anthramycin, maytansine alkaloids (such as DM-1 and DM-4), diketopiperazines, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, and cyclophosphamide and the like).
[0491] In some embodiments, the antigen-binding fragment can form part of a chimeric antigen receptor (CAR). In some embodiments, the chimeric antigen receptor is a fusion of a single-chain variable fragment (scFv) as described herein with a CD3-ζ transmembrane and intracellular domain. In some embodiments, the chimeric antigen receptor further includes an intracellular signaling domain from various co-stimulatory protein receptors (e.g., CD28, 41BB, ICOS). In some embodiments, the chimeric antigen receptor includes multiple signaling domains, such as CD3z-CD28-41BB or CD3z-CD28-OX40, to increase potency. Thus, in one aspect, the present disclosure also provides a cell (e.g., a T cell) expressing a chimeric antigen receptor as described herein.
[0492] In some embodiments, the scFv has one heavy chain variable domain and one light chain variable domain. In some embodiments, the scFv has two heavy chain variable domains and two light chain variable domains.
[0493] In some embodiments, the antibody or antigen-binding fragment thereof as described herein includes a heavy chain constant region (e.g., CH1, CH2, and / or CH3) selected from mouse IgG1, IgG2a, and IgG2b. In some embodiments, the antibody or antigen-binding fragment thereof as described herein includes a light chain constant region (e.g., CL) selected from mouse κ or λ CL.
[0494] In some embodiments, the antibody or antigen-binding fragment thereof as described herein includes a heavy chain constant region (e.g., CH1, CH2, and / or CH3) selected from human IgG (e.g., human IgG1, IgG2, IgG3, or IgG4). In some embodiments, the antibody or antigen-binding fragment thereof as described herein includes a light chain constant region (e.g., CL) selected from human κ or λ CL.
[0495] Antibody Characteristics
[0496] The antibody or antigen-binding fragment thereof as described herein can block the binding between CCR8 and the CCR8 ligand (e.g., CCL1). In some embodiments, by binding to CCR8, the antibody can inhibit the inhibitory function of CCL1-induced tumor-resident Treg cells. In some embodiments, the antibody can upregulate the immune response. In some embodiments, the antibody can deplete Treg cells (e.g., tumor-resident Treg cells). In some embodiments, the antibody has a reduced risk of inducing autoimmunity and a reduced risk of inducing systemic Treg cell depletion.
[0497] In some embodiments, the antibody or antigen-binding fragment thereof as described herein increases anti-tumor immunity by at least or about 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 100%.
[0498] In some embodiments, the antibody or antigen-binding fragment thereof as described herein has a lower risk of inducing autoimmunity or causing systemic Treg cell depletion. In some embodiments, compared with other therapeutic agents targeting Treg (e.g., anti-CCR4, CTLA4, OX40, or GITR antibodies), the antibody or antigen-binding fragment thereof as described herein has a reduced risk of inducing autoimmunity by at least or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%.
[0499] In some embodiments, an antibody or antigen-binding fragment thereof as described herein can reduce the activity or number of Treg cells (e.g., tumor-resident and / or Treg cells in the tumor microenvironment), e.g., by at least or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% compared to the activity or number of Treg cells when the antibody or antigen-binding fragment thereof is not administered.
[0500] In some embodiments, an antibody or antigen-binding fragment thereof as described herein can increase the activity or number of an immune response, immune cells (e.g., T cells, CD8+ T cells, CD4+ T cells, macrophages, antigen-presenting cells), e.g., by at least or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 5-fold, 10-fold, or 20-fold compared to the situation when the antibody or antigen-binding fragment thereof is not administered.
[0501] In some embodiments, an antibody or antigen-binding fragment thereof as described herein can effectively increase the Teff:Treg ratio, e.g., by at least or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 5-fold, 10-fold, or 20-fold compared to the situation when the antibody or antigen-binding fragment thereof is not administered.
[0502] In some embodiments, the antibody (or antigen-binding fragment thereof) specifically binds to CCR8 with a dissociation rate (koff) of less than 0.1 s -1 、less than 0.01 s -1 、less than 0.001 s -1 、less than 0.0001 s -1 、or less than 0.00001 s -1 (e.g., human CCR8, simian CCR8 (e.g., cynomolgus macaque (Macaca fascicularis)), murine CCR8, and / or chimeric CCR8). In some embodiments, the dissociation rate (koff) is greater than 0.01 s -1 、greater than 0.001 s -1 、greater than 0.0001 s -1 、greater than 0.00001 s -1 、or greater than 0.000001 s -1 .
[0503] In some embodiments, the kinetic binding rate (kon) is greater than 1×10 2 / Ms, greater than 1×10 3 / Ms, greater than 1×10 4 / Ms, greater than 1×10 5 / Ms or greater than 1×10 6 / Ms. In some embodiments, the kinetic association rate (kon) is less than 1×10 5 / Ms, less than 1×10 6 / Ms or less than 1×10 7 / Ms.
[0504] The affinity can be derived from the quotient of the kinetic rate constants (KD = koff / kon). In some embodiments, KD is less than 1×10 -6 M, less than 1×10 -7 M, less than 1×10 -8 M, less than 1×10 -9 M or less than 1×10 -10 M. In some embodiments, KD is less than 50 nM, 30 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM or 1 nM. In some embodiments, KD is greater than 1×10 -7 M, greater than 1×10 -8 M, greater than 1×10 -9 M, greater than 1×10 -10 M, greater than 1×10 -11 M or greater than 1×10 -12 M.
[0505] In some embodiments, the antibody or its antigen-binding fragment binds to human CCR8 at Y17, F21, D97, W99, F101, G102, C106, G179, C183, W194, K195, I196 and / or L278.
[0506] In some embodiments, the binding affinity of the antibody or its antigen-binding fragment as described herein can be measured by FACS. An exemplary procedure is shown in Example 4. In some embodiments, EC 50 is less than 25 μg / mL, less than 15 μg / mL, less than 10 μg / mL, less than 5 μg / mL, less than 2.5 μg / mL, less than 1 μg / mL, less than 0.5 μg / mL, less than 0.4 μg / mL, less than 0.3 μg / mL, less than 0.2 μg / mL, less than 0.15 μg / mL, less than 0.1 μg / mL or less than 0.05 μg / mL. In some embodiments, EC 50 is about 0.05 - 0.5 μg / mL, about 0.1 - 1 μg / mL, about 0.1 - 0.8 μg / mL, about 0.1 - 0.5 μg / mL, about 0.2 - 2 μg / mL, about 0.2 - 1 μg / mL or about 0.3 - 5 μg / mL.
[0507] In some embodiments, the blocking of the binding of an antibody or antigen-binding fragment thereof as described herein to hCCL1 and hCCR8 can be measured by a FLIPR Calcium 6 assay kit. In some embodiments, the EC 50 is less than 30 nM, 20 nM, 10 nM, 5 nM, 2.5 nM, 1.5 nM, or 1 nM. In some embodiments, the EC 50 is about 1 - 10 nM, 1.5 - 20 nM, or 2.5 - 30 nM. In some embodiments, the maximal inhibition is greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%. In some embodiments, the maximal inhibition is less than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.
[0508] In some embodiments, the antibody can bind to one or more of human CCR2, human CCR4, human CCR5, human CCR8, and human CX3CR1. In some embodiments, the antibody does not bind to one or more of human CCR2, human CCR4, human CCR5, human CCR8, and human CX3CR1.
[0509] In some embodiments, antibody-dependent cell cytotoxicity (ADCC) can be determined by a reporter gene bioassay (ADCC reporter gene bioassay). In some embodiments, the EC 50 is less than 25 μg / mL, less than 15 μg / mL, less than 10 μg / mL, less than 5 μg / mL, less than 2.5 μg / mL, less than 1 μg / mL, less than 0.5 μg / mL, less than 0.4 μg / mL, less than 0.3 μg / mL, less than 0.2 μg / mL, less than 0.15 μg / mL, less than 0.1 μg / mL, less than 0.05 μg / mL, less than 0.025 μg / mL, less than 0.01 μg / mL, less than 0.005 μg / mL, or less than 0.0025 μg / mL. In some embodiments, the EC 50 is about 0.0025 - 0.05 μg / mL, about 0.005 - 0.1 μg / mL, about 0.005 - 0.05 μg / mL, about 0.005 - 0.01 μg / mL, about 0.01 - 0.2 μg / mL, or about 0.025 - 0.3 μg / mL.
[0510] General techniques for measuring the affinity of an antibody for an antigen include, for example, flow cytometry, FACS, ELISA, RIA, and surface plasmon resonance (SPR). In some embodiments, the antibody binds to human CCR8 (SEQ ID NO: 43).
[0511] In some embodiments, thermal stability is determined. In some embodiments, an antibody or antigen-binding fragment as described herein can have a Tm greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, or 95°C. In some embodiments, the Tm is less than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, or 95°C.
[0512] In some embodiments, the antibody has a tumor growth inhibition percentage (TGI%) greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200%. In some embodiments, the antibody has a tumor growth inhibition percentage less than 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200%. The TGI% can be determined, for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days after the start of treatment, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the start of treatment. As used herein, the tumor growth inhibition percentage (TGI%) is calculated using the following formula:
[0513] TGI(%) = [1 - (Ti - T0) / (Vi - V0)] × 100
[0514] Ti is the mean tumor volume in the treatment group on day i. T0 is the mean tumor volume in the treatment group on day 0. Vi is the mean tumor volume in the control group on day i. V0 is the mean tumor volume in the control group on day 0.
[0515] In some embodiments, an antibody or antigen-binding fragment thereof as described herein blocks the binding of CCR8 to its ligand (e.g., CCL1). In some embodiments, an antibody or antigen-binding fragment thereof as described herein inhibits the inhibitory function of CCL-1-induced tumor-resident Treg cells.
[0516] In some embodiments, the antibody or antigen-binding fragment can induce complement-dependent cytotoxicity (CMC) and / or antibody-dependent cell cytotoxicity (ADCC) and kill cells expressing CCR8 (e.g., Treg cells).
[0517] In some embodiments, the antibody or antigen-binding fragment has a functional Fc region. In some embodiments, the effector function of the functional Fc region is antibody-dependent cell-mediated cytotoxicity (ADCC). In some embodiments, the antibody or antigen-binding fragment can induce complement-mediated cytotoxicity (CMC).
[0518] In some embodiments, the Fc region is human IgG1, human IgG2, human IgG3, or human IgG4. In some embodiments, the antibody is a human IgG1 antibody.
[0519] In some embodiments, the antibody or antigen-binding fragment does not have a functional Fc region. For example, the antibody or antigen-binding fragment is a Fab, Fab', F(ab') 2 and Fv fragment. In some embodiments, the Fc region has an LALA mutation (L234A and L235A mutations in EU numbering), or an LALA-PG mutation (L234A, L235A, P329G mutations in EU numbering).
[0520] In some embodiments, the Fc region is human IgG1, human IgG2, human IgG3, or human IgG4. In some embodiments, the antibody is a human IgG1 antibody, optionally having an SI mutation, an LALA mutation, an N297A mutation, a YTE mutation, and / or an FLAA mutation. In some embodiments, the antibody is a human IgG4 antibody, optionally having an SI mutation, an LALA mutation, an N297A mutation, a YTE mutation, and / or an FLAA mutation.
[0521] In some embodiments, the antibody or antigen-binding fragment does not have a functional Fc region. For example, the antibody or antigen-binding fragment is a Fab, Fab', F(ab') 2and Fv fragments. In some embodiments, the Fc region has an LALA mutation (L234A and L235A mutations according to EU numbering), or an LALA-PG mutation (L234A, L235A, P329G mutations according to EU numbering). In some embodiments, the Fc region has an FLAA mutation (F234A and L235A according to EU numbering). In some embodiments, the Fc has an SI mutation (S239D and I332E mutations according to EU numbering). In some embodiments, the Fc has an N297A mutation according to EU numbering. In some embodiments, the Fc has a YTE mutation (M252Y, S254T, and T256E according to EU numbering).
[0522] Method for preparing an anti-CCR8 antibody
[0523] An isolated human CCR8 membrane protein can be used as an immunogen to generate antibodies using standard techniques for preparing polyclonal and monoclonal antibodies. Polyclonal antibodies can be generated in an animal by multiple injections (e.g., subcutaneous or intraperitoneal injection) of the antigenic peptide or protein. In some embodiments, the antigenic peptide or protein is injected together with at least one adjuvant. In some embodiments, the antigenic peptide or protein can be conjugated to an agent that is immunogenic in the species to be immunized. The animal can be injected with the antigenic peptide or protein more than once (e.g., two, three, or four times).
[0524] A full-length polypeptide or protein, or an antigenic peptide fragment thereof, can be used as an immunogen. The antigenic peptide of the protein includes at least 8 (e.g., at least 10, 15, 20, or 30) amino acid residues of the amino acid sequence of CCR8 and encompasses an epitope of the protein such that an antibody generated against the peptide forms a specific immune complex with the protein. As described above, the full-length sequence of human CCR8 is known in the art (SEQ ID NO:43).
[0525] An immunogen is generally used to prepare antibodies by immunizing a suitable subject (e.g., a human or a transgenic animal expressing at least one human immunoglobulin locus). A suitable immunogenic preparation can contain, for example, a recombinantly expressed or chemically synthesized polypeptide (e.g., a fragment of human CCR8). The preparation can also include an adjuvant (such as Freund's complete or incomplete adjuvant) or a similar immunostimulant.
[0526] Polyclonal antibodies can be prepared by immunizing a suitable subject with a CCR8 polypeptide or its antigenic peptide (e.g., a portion of CCR8) as described above. Antibody titers in the immunized subject can be monitored over time using standard techniques, such as enzyme-linked immunosorbent assay (ELISA), using immobilized CCR8 polypeptide or peptide. If desired, antibody molecules can be isolated from a mammal (e.g., from blood) and further purified by well-known techniques, such as protein A or protein G chromatography, to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the specific antibody titer is highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler et al. (Nature 256:495-497, 1975), human B cell hybridoma technique (Kozbor et al., Immunol. Today 4:72, 1983), EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985) or trioma technique. Techniques for generating hybridomas are well known (see generally "Current Protocols in Immunology", 1994, edited by Coligan et al., John Wiley & Sons, Inc., New York, NY). Hybridoma cells producing monoclonal antibodies are detected by screening the hybridoma culture supernatant for antibodies that bind to the polypeptide or epitope of interest, e.g., using a standard ELISA assay.
[0527] The antibodies disclosed herein can be derived from animals of any species, including mammals. Non-limiting examples of natural antibodies include antibodies derived from humans, primates (e.g., monkeys and apes), cows, pigs, horses, sheep, camelids (e.g., camels and llamas), chickens, goats, and rodents (e.g., rats, mice, hamsters, and rabbits, including transgenic rodents genetically engineered to produce human antibodies).
[0528] Human and humanized antibodies include antibodies having variable and constant regions derived from human germline immunoglobulin sequences (or having the same amino acid sequence as an antibody derived from human germline immunoglobulin sequences). The antibody can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by in vitro random or site-specific mutagenesis or in vivo somatic mutation), e.g., in the CDRs.
[0529] Humanized antibodies typically graft non-human CDRs onto a human framework (FR). Thus, a humanized antibody has one or more amino acid sequences introduced therein from a non-human source. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can essentially be carried out, for example, by replacing the corresponding sequences of a human antibody with rodent CDRs or CDR sequences. These methods are described, for example, in Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse." Nature
[0530] 321.6069(1986):522; Riechmann et al., "Reshaping human antibodies for therapy." Nature
[0531] 332.6162(1988):323; Dall Acqua et al., "Antibody humanization by framework shuffling." Methods 36.1(2005):43 - 60, the full texts of the above-mentioned documents are incorporated herein by reference. Thus, a "humanized" antibody is a chimeric antibody in which a small part of the intact human V domain is replaced by the corresponding sequence from a non-human species. In fact, humanized antibodies are typically mouse antibodies in which some CDR residues and some FR residues are replaced by residues from similar sites in a human antibody.
[0532] The selection of human VH and VL domains for the preparation of humanized antibodies is very important for reducing immunogenicity. According to the so-called "best-fit" method, the V domain sequences of mouse antibodies are screened against the entire library of known human domain sequences. Then, the human sequence that is closest to the mouse sequence is accepted as the human FR of the humanized antibody (Sims et al., "A humanized CD18 antibody can block function without cell destruction", The Journal of Immunology 151.4(1993):2296 - 2308; Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins", Journal of molecular biology 196.4(1987):901 - 917).
[0533] More importantly, antibody humanization retains high specificity and affinity for the antigen as well as other favorable biological properties. To achieve this goal, humanized antibodies can be prepared by using three-dimensional models of the parental and humanized sequences to analyze the parental sequence and various conceptual humanized products. Three-dimensional immunoglobulin models are generally available and familiar to those skilled in the art. Computer programs are available that illustrate and display the possible three-dimensional conformational structures of selected candidate immunoglobulin sequences. Examination of these displays allows analysis of the possible role of residues in the function of the candidate immunoglobulin sequence, i.e., analysis of the residues that affect the ability of the candidate immunoglobulin to bind its antigen. By this method, FR residues can be selected and combined from the acceptor and the introduced sequences in order to obtain desired antibody characteristics, such as increased affinity for the target antigen.
[0534] Generally, amino acid sequence variants of human, humanized or chimeric anti-CCR8 antibodies will contain an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% percent identity to the sequence present in the original antibody light or heavy chain.
[0535] In some embodiments, mice having a humanized heavy chain immunoglobulin locus and a humanized κ chain immunoglobulin locus (e.g., RenMab TM mice) are used to generate antibodies. The heavy chain immunoglobulin locus is the region on a chromosome that contains the antibody heavy chain genes. The locus can include, for example, human IGHV (variable) genes, human IGHD (diversity) genes, human IGHJ (joining) genes, and murine heavy chain constant domain genes. The κ chain immunoglobulin locus is the region on a chromosome that contains the genes encoding the antibody light chain (κ chain). The κ chain immunoglobulin locus can include, for example, human IGKV (variable) genes, human IGKJ (joining) genes, and murine light chain constant domain genes. For a detailed description of RenMab TM mice, see PCT / CN2020 / 075698 or US20200390073A1, which are incorporated herein by reference in their entireties.
[0536] In some embodiments, mice having a humanized heavy chain immunoglobulin locus and a humanized κ chain immunoglobulin locus (e.g., RenLite TMAntibodies are produced by (e.g., mice). The heavy chain immunoglobulin locus is the region on a chromosome that contains antibody heavy chain genes. The locus can include, for example, human IGHV (variable) genes, human IGHD (diversity) genes, human IGHJ (joining) genes, and murine heavy chain constant domain genes. The κ-chain immunoglobulin locus is the region on a chromosome that contains genes encoding the common light chain. The κ-chain immunoglobulin locus can include, for example, human IGKV (variable) genes, human IGKJ (joining) genes, and murine light chain constant domain genes. Regarding RenLite TM A detailed description of the mouse can be found in PCT / CN2021 / 097652, which is incorporated herein by reference in its entirety.
[0537] Antibodies produced by mice have a full-length human VH, a full-length human VL, and a murine constant region. In some embodiments, the human VH and human VL are linked to a human IgG constant region (e.g., IgG1, IgG2, IgG3, and IgG4).
[0538] Identity or homology relative to the original sequence is generally the percentage of amino acid residues within a candidate sequence that are identical to the sequences present within a human, humanized, or chimeric anti-CCR8 antibody or fragment, after aligning the candidate sequence with the original sequence and introducing gaps as necessary to achieve maximum percent sequence identity, and without considering any conservative substitutions as part of the sequence identity.
[0539] Additional modifications can be made to the anti-CCR8 antibody or antigen-binding fragment. For example, cysteine residues can be introduced into the Fc region, allowing for the formation of interchain disulfide bonds in this region. The resulting homodimeric antibodies can have any increased in vitro and / or in vivo half-life. Homodimeric antibodies with increased in vitro and / or in vivo half-life can also be prepared using heterobifunctional crosslinking agents, such as, for example, Wolff et al. (“Monoclonal antibody homodimers: enhanced antitumor activity in nude mice”, Cancer research 53.11 (1993): 2560 - 2565). Alternatively, antibodies with a dual Fc region can be engineered.
[0540] In some embodiments, the anti-CCR8 antibody or its antigen-binding fragment can be covalently modified. These covalent modifications can be made by chemical or enzymatic synthesis, or by enzymatic or chemical cleavage. Other types of covalent modifications of the antibody or antibody fragment are introduced into the molecule by reacting the targeted amino acid residues of the antibody or fragment with an organic derivatizing agent capable of reacting with selected side chains or N-terminal or C-terminal residues.
[0541] In some embodiments, antibody variants are provided that have a carbohydrate structure lacking fucose (directly or indirectly) linked to the Fc region. For example, the amount of fucose in such antibody compositions can be from 1% to 80%, from 1% to 65%, from 5% to 65%, or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297 relative to the sum of all sugar structures linked to Asn297 (e.g., complex, hybrid, and high mannose structures), as measured by MALDI-TOF mass spectrometry (e.g., as described in WO 2008 / 077546). Asn297 refers to the asparagine residue located at approximately position 297 in the Fc region (Eu numbering of Fc region residues; or position 314 in Kabat numbering); however, due to minor sequence variations in the antibody, Asn297 can also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylation variants can have improved ADCC function. In some embodiments, to reduce glycan heterogeneity, the Fc region of the antibody can be further engineered to replace the asparagine at position 297 with alanine (N297A).
[0542] In some embodiments, to promote production efficiency by avoiding Fab-arm exchange, the Fc region of the antibody is further engineered to replace the serine at position 228 (EU numbering) of IgG4 with proline (S228P). For a detailed description of the S228 mutation, see, for example, Silva et al., “The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation", Journal of Biological Chemistry 290.9 (2015):5462 - 5469, which is incorporated herein by reference in its entirety.
[0543] Recombinant vector
[0544] The present disclosure also provides recombinant vectors (e.g., expression vectors) comprising the isolated polynucleotides disclosed herein (e.g., polynucleotides encoding the polypeptides disclosed herein), host cells into which these recombinant vectors are introduced (i.e., such that the host cells contain the polynucleotide and / or the vector comprising the polynucleotide), and recombinant antibody polypeptides or fragments thereof produced by recombinant techniques.
[0545] As used herein, a "vector" is any construct that is capable of delivering one or more polynucleotides of interest to a host cell when the vector is introduced into the host cell. An "expression vector" is capable of delivering one or more polynucleotides of interest to a host cell into which the expression vector has been introduced and expressing them as an encoded polypeptide. Thus, in an expression vector, the polynucleotide of interest is positioned for expression in the vector by being operably linked to regulatory elements (such as promoters, enhancers, and / or poly-A tails) within the vector or in the genome of the host cell at or near or flanking the integration site of the polynucleotide of interest, such that the polynucleotide of interest will be translated in the host cell into which the expression vector has been introduced.
[0546] Vectors can be introduced into host cells by methods known in the art, such as electroporation, chemical transfection (e.g., DEAE-dextran), transformation, transfection, and infection and / or transduction (e.g., with a recombinant virus). Thus, non-limiting examples of vectors include viral vectors (which can be used to produce recombinant viruses), naked DNA or RNA, plasmids, cosmids, phage vectors, and DNA or RNA expression vectors associated with cationic condensing agents.
[0547] In some embodiments, viral expression systems (e.g., vaccinia or other poxviruses, retroviruses, or adenoviruses) are used to introduce the polynucleotides disclosed herein (e.g., polynucleotides encoding the polypeptides disclosed herein), which may involve the use of non-pathogenic (defective), replication-competent viruses, or replication-defective viruses may be used. In the latter case, viral replication typically occurs only in complementary virus packaging cells. Suitable systems are disclosed, for example, in Fisher-Hoch et al., 1989, Proc. Natl. Acad. Sci. USA 86:317-321; Flexner et al., 1989, Ann. N.Y. Acad Sci. 569:86-103; Flexner et al., 1990, Vaccine, 8:17-21; U.S. Pat. Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89 / 01973; U.S. Pat. No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91 / 02805; Berchner-Biotechniques, 6:616-627, 1988; Rosenfeld et al., 1991, Science, 252:431-434; Kolls et al., 1994, Proc. Natl. Acad. Sci. USA, 91:215-219; Kass-Eisler et al., 1993, Proc. Natl. Acad. Sci. USA, 90:11498-11502; Guzman et al., 1993, Circulation, 88:2838-2848; and Guzman et al., 1993, Cir. Res., 73:1202-1207. Techniques for integrating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA can also be "naked," as described, for example, in Ulmer et al., 1993, Science, 259:1745-1749, and Cohen, 1993, Science, 259:1691-1692. Uptake of naked DNA can be increased by coating the DNA on biodegradable beads that are efficiently transported into cells.
[0548] For expression, a DNA insert fragment comprising a polynucleotide encoding an antibody or polypeptide disclosed herein can be operably linked to a suitable promoter (e.g., a heterologous promoter), such as the bacteriophage λPL promoter, the Escherichia coli (E. coli) lac, trp, and tac promoters, the SV40 early and late promoters, and the promoter of the retroviral LTR, among others. Other suitable promoters are known to those skilled in the art. In some embodiments, the promoter is the cytomegalovirus (CMV) promoter. The expression construct may also contain a transcription start and termination site and include a ribosome binding site for translation in the transcribed region. The coding portion of the mature transcript expressed by the construct may include a translation start codon at the beginning of the polypeptide to be translated and a stop codon (UAA, UGA, or UAG) at an appropriate position at the end of the polypeptide to be translated.
[0549] As described above, the expression vector may include at least one selectable marker. Such markers include the dihydrofolate reductase or neomycin resistance gene for eukaryotic cell culture and the tetracycline or ampicillin resistance gene for culture in E. coli and other bacteria. Representative examples of suitable hosts include, but are not limited to, bacterial cells such as E. coli, Streptomyces, and Salmonella typhimurium cells; fungal cells such as yeast cells; insect cells such as Drosophila S2 and Spodoptera frugiperda Sf9 cells; animal cells such as CHO, COS, Bowes melanoma, and HK 293 cells; and plant cells. Suitable media and conditions for the host cells described herein are known in the art.
[0550] Non-limiting vectors for bacteria include pQE70, pQE60, and pQE-9 obtained from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A obtained from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 obtained from Pharmacia. Non-limiting eukaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1, and pSG obtained from Stratagene; and pSVK3, pBPV, pMSG, and pSVL obtained from Pharmacia. Other suitable vectors will be apparent to those skilled in the art.
[0551] Suitable non-limiting bacterial promoters include the Escherichia coli lacI and lacZ promoters, T3 and T7 promoters, gpt promoter, λPR and PL promoters, and trp promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, HSV thymidine kinase promoter, early and late SV40 promoters, promoters of retroviral LTRs (such as the promoter of Rous sarcoma virus (RSV)), and metallothionein promoters (such as the mouse metallothionein-I promoter).
[0552] In Saccharomyces cerevisiae, many vectors containing constitutive or inducible promoters can be used, such as the α-factor, alcohol oxidase, and PGH.
[0553] Introduction of the construct into the host cell can be achieved by calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. These methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986), which is incorporated herein by reference in its entirety.
[0554] Transcription of DNA encoding the antibodies of the present disclosure in higher eukaryotes can be increased by inserting enhancer sequences into the vector. Enhancers are cis-acting elements of DNA, usually about 10 bp - 300 bp, which function to increase the transcriptional activity of promoters in a given host cell type. Examples of enhancers include the SV40 enhancer located on the late side of the origin of replication at base pairs 100 - 270, the cytomegalovirus early promoter enhancer, the polyomavirus enhancer on the late side of the origin of replication, and the adenovirus enhancer.
[0555] To enable the translated protein to be secreted into the lumen of the endoplasmic reticulum, the periplasmic space, or the extracellular environment, an appropriate secretion signal can be incorporated into the expressed polypeptide. The signal can be an endogenous signal of the polypeptide or a heterologous signal.
[0556] The polypeptide (e.g., antibody) can be expressed in a modified form, such as a fusion protein (e.g., GST fusion protein) or with a histidine tag, and can include not only a secretion signal but also additional heterologous functional regions. For example, a region of additional amino acids (especially charged amino acids) can be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent processing and storage. In addition, a peptide moiety can be added to the polypeptide to facilitate purification. These regions can be removed before the final preparation of the polypeptide. Adding peptide moieties to polypeptides to effect secretion or excretion, improve stability, and facilitate purification, etc. are conventional techniques well known in the art.
[0557] Treatment method
[0558] The antibodies or antigen-binding fragments thereof of the present disclosure can be used for various therapeutic purposes.
[0559] In one aspect, the present disclosure provides methods for treating cancer in a subject, methods for reducing the rate of increase in tumor volume over time in a subject, methods for reducing the risk of forming metastases, or methods for reducing the risk of forming additional metastases in a subject. In some embodiments, the treatment can terminate, slow down, delay, or inhibit the progression of cancer. In some embodiments, the treatment can reduce the number, severity, and / or duration of one or more symptoms of cancer in the subject.
[0560] In one aspect, the present disclosure features methods comprising administering a therapeutically effective amount of an antibody or an antigen-binding fragment thereof disclosed herein to a subject in need thereof (e.g., a subject having or identified or diagnosed as having cancer), such as breast cancer (e.g., triple-negative breast cancer), carcinoid, cervical cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, small cell lung cancer, lymphoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, colorectal cancer, thyroid cancer, bladder cancer, urethral cancer, gastric cancer, testicular cancer, gallbladder cancer, cholangiocarcinoma, esophageal cancer, thymic cancer, acute myeloid leukemia, lymphoblastic lymphoma, transitional cell carcinoma, or hematological malignancies. In some embodiments, the cancer is unresectable melanoma or metastatic melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bladder cancer, or metastatic hormone-refractory prostate cancer. In some embodiments, the subject has a solid tumor. In some embodiments, the cancer is squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), triple-negative breast cancer (TNBC), or colorectal cancer. In some embodiments, the subject has Hodgkin lymphoma. In some embodiments, the subject has triple-negative breast cancer (TNBC), gastric cancer, urothelial cancer, Merkel cell carcinoma, or head and neck cancer. In some embodiments, the cancer is melanoma, pancreatic cancer, mesothelioma, hematological malignancies, especially non-Hodgkin lymphoma, lymphoma, chronic lymphocytic leukemia, or advanced solid tumors.
[0561] In some embodiments, the subject has a PD-1 inhibitor-resistant cancer. In some embodiments, the subject is non-responsive to anti-PD-1 antibody or anti-PD-L1 antibody treatment.
[0562] In some embodiments, the compositions and methods disclosed herein can be used to treat patients at risk of cancer. Cancer patients can be identified by various methods known in the art.
[0563] In one aspect, the present disclosure provides methods of treating, preventing, or reducing the risk of development of a disease associated with an abnormal or unwanted immune response (e.g., an autoimmune disease).
[0564] As used herein, an "effective amount" refers to an amount or dose sufficient to achieve a beneficial or desired result, including termination, slowing, delaying, or inhibition of the progression of a disease (e.g., cancer). The effective amount will vary depending on, for example, the age and weight of the subject to which the antibody, antigen-binding fragment, antibody-encoding polynucleotide, vector comprising the polynucleotide, and / or composition thereof is to be administered, the severity of the symptoms, and the route of administration, and thus administration can be determined on an individual basis.
[0565] The effective amount can be administered in one or more administrations. For example, an effective amount of an antibody or antigen-binding fragment is an amount sufficient to ameliorate, terminate, stabilize, reverse, inhibit, slow, and / or delay the progression of an autoimmune disease or cancer in a patient, or is an amount sufficient to ameliorate, terminate, stabilize, reverse, slow, and / or delay the proliferation in vitro of a cell (e.g., a biopsy cell, any of the cancer cells described herein, or a cell line (e.g., a cancer cell line)). As understood in the art, the effective amount of an antibody or antigen-binding fragment can vary depending on, inter alia, the patient's medical history and other factors such as the type (and / or dose) of the antibody used.
[0566] The effective amount and dosing regimen of the antibodies, polynucleotides encoding antibodies, and / or compositions disclosed herein can be determined empirically, and making such determinations is within the skill in the art. Those skilled in the art will understand that the dose to be administered will vary depending on, for example, the mammal to which the antibodies, polynucleotides encoding antibodies, antigen-binding fragments, and / or compositions disclosed herein are to be administered, the route of administration, the specific type of the antibodies, polynucleotides encoding antibodies, antigen-binding fragments, and / or compositions disclosed herein used, and other drugs being administered to the mammal.
[0567] The typical daily dose of an effective amount of an antibody is from 0.01 mg / kg to 100 mg / kg (mg / kg of patient body weight). In some embodiments, the dose can be less than 100 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg or 0.1 mg / kg. In some embodiments, the dose can be greater than 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg, 0.1 mg / kg, 0.05 mg / kg or 0.01 mg / kg. In some embodiments, the dose is about 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.9 mg / kg, 0.8 mg / kg, 0.7 mg / kg, 0.6 mg / kg, 0.5 mg / kg, 0.4 mg / kg, 0.3 mg / kg, 0.2 mg / kg or 0.1 mg / kg.
[0568] In any of the methods described herein, at least one antibody, an antigen-binding fragment thereof or a pharmaceutical composition (e.g., any of the antibodies, antigen-binding fragments or pharmaceutical compositions described herein) and optionally at least one additional therapeutic agent can be administered to a subject at least once a week (e.g., once a week, twice a week, three times a week, four times a week, once a day, twice a day or three times a day). In some embodiments, at least two different antibodies and / or antigen-binding fragments are administered in the same composition (e.g., a liquid composition). In some embodiments, at least one antibody or antigen-binding fragment and at least one additional therapeutic agent are administered in the same composition (e.g., a liquid composition). In some embodiments, at least one antibody or antigen-binding fragment and at least one additional therapeutic agent are administered in two different compositions (e.g., a liquid composition containing at least one antibody or antigen-binding fragment and a solid oral composition containing at least one additional therapeutic agent). In some embodiments, at least one additional therapeutic agent is administered in the form of a pill, tablet or capsule. In some embodiments, at least one additional therapeutic agent is administered in a sustained-release oral formulation.
[0569] In some embodiments, one or more additional therapeutic agents may be administered to a subject before or after administering at least one antibody, antigen-binding antibody fragment, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein). In some embodiments, one or more additional therapeutic agents and at least one antibody, antigen-binding antibody fragment, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein) are administered to a subject such that there is an overlap in the biological activity periods of the one or more additional therapeutic agents and the at least one antibody or antigen-binding fragment (e.g., any of the antibodies or antigen-binding fragments described herein) in the subject.
[0570] In some embodiments, at least one antibody, antigen-binding antibody fragment, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein) may be administered to a subject over an extended period of time (e.g., over a period of at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, or 5 years). A skilled medical professional may use any of the methods described herein to determine the length of the treatment period to diagnose or track treatment efficacy (e.g., observe at least one symptom of cancer). As described herein, a skilled medical professional may also vary the type and amount (e.g., increase or decrease) of the antibody or antigen-binding antibody fragment (and / or one or more additional therapeutic agents) administered to the subject, and may also adjust (e.g., increase or decrease) the dose or frequency of the at least one antibody or antigen-binding antibody fragment (and / or one or more additional therapeutic agents) administered to the subject based on an assessment of treatment efficacy (e.g., using any of the methods described herein and known in the art).
[0571] In some embodiments, one or more additional therapeutic agents may be administered to a subject. The additional therapeutic agent may include one or more inhibitors selected from the group consisting of: B-Raf inhibitors, EGFR inhibitors, MEK inhibitors, ERK inhibitors, K-Ras inhibitors, c-Met inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, Akt inhibitors, mTOR inhibitors, PI3K / mTOR dual inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, and isocitrate dehydrogenase 1 (IDH1) and / or isocitrate dehydrogenase 2 (IDH2) inhibitors. In some embodiments, the additional therapeutic agent is an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (e.g., epacadostat).
[0572] In some embodiments, the additional therapeutic agent may include one or more inhibitors selected from the group consisting of: HER3 inhibitors, LSD1 inhibitors, MDM2 inhibitors, BCL2 inhibitors, CHK1 inhibitors, inhibitors of the activated hedgehog signaling pathway, and agents that selectively degrade estrogen receptors.
[0573] In some embodiments, the additional therapeutic agent may include one or more therapeutic agents selected from the group consisting of: trabectedin, nab-paclitaxel, trebananib, cediranib, palbociclib, everolimus, fluoropyrimidine, IFL, regorafenib, Reolysin, Alimta, Zykadia, Sutent, temsirolimus, axitinib, sorafenib, Votrient, pazopanib, IMA-901, AGS-003, cabozantinib, vinflunine, Hsp90 inhibitors, Ad-GM-CSF, temazolomide, IL-2, IFNa, vinblastine, Thalomid, dacarbazine, cyclophosphamide, lenalidomide, azacytidine, bortezomid, amrubicine, carfilzomib, pralatrexate, and enzastaurin.
[0574] In some embodiments, the additional therapeutic agent may include one or more therapeutic agents selected from the group consisting of: adjuvants, TLR agonists, tumor necrosis factor (TNF)α, IL-1, HMGB1, IL-10 antagonists, IL-4 antagonists, IL-13 antagonists, IL-17 antagonists, HVEM antagonists, ICOS agonists, therapies targeting CX3CL1, therapies targeting CXCL9, therapies targeting CXCL10, therapies targeting CCL5, LFA-1 agonists, ICAM1 agonists, and selectin agonists.
[0575] In some embodiments, carboplatin, albumin-bound paclitaxel, paclitaxel, cisplatin, pemetrexed, gemcitabine, FOLFOX, or FOLFIRI is administered to a subject.
[0576] In some embodiments, the additional therapeutic agent is an anti-OX40 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-LAG-3 antibody, an anti-TIGIT antibody, an anti-BTLA antibody, an anti-CTLA-4 antibody, an anti-B7-H3 antibody, an anti-CLDN18 antibody, an anti-SIGLEC15 antibody, an anti-41BB antibody, an anti-CD40 antibody, or an anti-GITR antibody.
[0577] In some embodiments, the additional therapeutic agent is a PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody. Exemplary anti-PD-1 antibodies include, for example, Pembrolizumab, Nivolumab, Cemiplimab, Spartalizumab, Camrelizumab, Sintilimab, Tislelizumab, Toripalimab, and Dostarlimab. Exemplary anti-PD-L1 antibodies include, for example, Atezolizumab, Avelumab, Durvalumab, and KN035.
[0578] Pharmaceutical Compositions and Routes of Administration
[0579] Also provided herein are pharmaceutical compositions comprising at least one (e.g., one, two, three, or four) antibody or antigen-binding fragment described herein. Two or more (e.g., two, three, or four) of any of the antibodies or antigen-binding fragments described herein can be present in the pharmaceutical composition in any combination. The pharmaceutical compositions can be formulated in any manner known in the art.
[0580] The pharmaceutical compositions are formulated to be compatible with their intended route of administration (e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal). The compositions can include sterile diluents (e.g., sterile water or saline), fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents, antibacterial or antifungal agents (such as benzyl alcohol or methylparabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.), antioxidants (such as ascorbic acid or sodium bisulfite), chelating agents (such as ethylenediaminetetraacetic acid), buffering agents (such as acetates, citrates, or phosphates), and isotonic agents (such as sugars (e.g., glucose), polyols (e.g., mannitol or sorbitol), or salts (e.g., sodium chloride)), or any combination thereof. Liposome suspensions can also be used as pharmaceutically acceptable carriers. The formulations of the compositions can be prepared and encapsulated in ampoules, disposable syringes, or multi-dose vials. When required (such as in injectable formulations, for example), appropriate fluidity can be maintained by, for example, using coatings (such as lecithin) or surfactants. The absorption of the antibody or its antigen-binding fragment can be prolonged by including agents that delay absorption (e.g., aluminum monostearate and gelatin). Alternatively, controlled release can be achieved by implants and microencapsulation delivery systems, which can include biodegradable, biocompatible polymers (e.g., ethylene-vinyl acetate copolymer, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid).
[0581] Compositions containing one or more of any of the antibodies or antigen-binding fragments described herein can be formulated for parenteral (e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal) administration in unit dosage form (i.e., physically discrete units containing a predetermined quantity of the active compound, to facilitate administration and ensure dose uniformity).
[0582] The pharmaceutical compositions for parenteral administration are preferably sterile and substantially isotonic and are produced under good manufacturing practice (GMP) conditions. The pharmaceutical compositions can be provided in unit dosage form (i.e., the dose for a single administration). The pharmaceutical compositions can be formulated using one or more physiologically acceptable carriers, diluents, excipients, or adjuvants. The formulation depends on the selected route of administration. For injection, the antibody can be formulated in an aqueous solution, preferably in a physiologically compatible buffer to reduce discomfort at the injection site. The solution can contain formulating agents such as suspending agents, stabilizers, and / or dispersing agents. Alternatively, the antibody can be in lyophilized form for formulation with a suitable solvent (e.g., sterile pyrogen-free water) before use.
[0583] The toxicity and efficacy of the compositions can be determined in cell cultures or experimental animals (e.g., monkeys) by standard pharmaceutical methods. For example, the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population) can be determined: the therapeutic index is the ratio of LD50:ED50. Agents with a high therapeutic index are preferably shown. When an agent exhibits adverse side effects, care should be taken to minimize potential damage (i.e., reduce adverse side effects). Toxicity and efficacy can be determined by other standard pharmaceutical methods.
[0584] Data obtained from cell culture assays and animal studies can be used to formulate appropriate doses of any given agent for a subject (e.g., a human). A therapeutically effective amount of one or more (e.g., one, two, three, or four) antibodies or antigen-binding fragments thereof (e.g., any of the antibodies or antibody fragments described herein) will be an amount that treats a disease (e.g., kills cancer cells) in a subject (e.g., a human subject identified as having cancer) or a subject identified as being at risk of developing a disease (e.g., a subject who previously had cancer but is now cured), or reduces the severity, frequency, and / or duration of one or more symptoms of a disease in a subject (e.g., a human). The effectiveness and dosage of any of the antibodies or antigen-binding fragments described herein can be determined by a healthcare professional or a veterinary professional using methods known in the art and by observing one or more symptoms of the disease in a subject (e.g., a human). Certain factors can affect the dosage and schedule required to effectively treat a subject (e.g., the severity of the disease or disorder, previous treatments, the general health and / or age of the subject, and the presence of other diseases).
[0585] Exemplary doses include milligram or microgram amounts of any one of the antibodies or antigen-binding fragments described herein per kilogram of subject body weight (e.g., from about 1 μg / kg to about 500 mg / kg; from about 100 μg / kg to about 500 mg / kg; from about 100 μg / kg to about 50 mg / kg; from about 10 μg / kg to about 5 mg / kg; from about 10 μg / kg to about 0.5 mg / kg; from about 1 μg / kg to about 50 μg / kg; from about 1 mg / kg to about 10 mg / kg; or from about 1 mg / kg to about 5 mg / kg). Although these doses cover a wide range, one of ordinary skill in the art will understand that the potencies of therapeutic agents, including antibodies and their antigen-binding fragments, vary and that an effective amount can be determined by methods known in the art. Generally, a relatively low dose is administered first, and then the attending healthcare professional or veterinary professional (in the case of therapeutic applications) or researcher (when working in the development stage) can gradually increase the dose until an appropriate response is obtained. In addition, it should be understood that the specific dose level for any particular subject will depend on a variety of factors, including the activity of the specific compound used, the age, weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, and the half-life of the antibody or antibody fragment in the body.
[0586] The pharmaceutical composition may be contained in a container, package, or dispenser together with instructions for administration. The present disclosure also provides methods for preparing antibodies or antigen-binding fragments thereof for various uses as described herein.
[0587] Examples
[0588] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
[0589] Example 1. Generation of anti-CCR8 antibodies
[0590] To generate antibodies against human CCR8, RenMice TM mice (i.e., engineered mice comprising DNA encoding the variable regions of the human immunoglobulin heavy and κ light chains, such as RenMab TM mice, RenLite TM mice) were immunized with human CCR8 protein. The antibody immune response was monitored by antigen-specific immunoassays.
[0591] A total of 4 immunizations were performed. Each immunization was spaced two weeks apart. Five to six days after the last immunization, retro-orbital blood was collected and the antibody titer in the serum was determined by fluorescence-activated cell sorting (FACS).
[0592] Spleen tissue was then collected and ground. Splenocytes were first selected by CD3ε microbeads and anti-mouse IgM microbeads and then fused with SP2 / 0 cells (to produce hybridoma cells). The cells were then seeded in 96-well plates containing hypoxanthine-aminopterin-thymidine (HAT) medium.
[0593] Hybridoma supernatants were initially screened using FACS in 96-well plates following standard procedures. Passage is performed. Briefly, positive wells identified during the primary screening are transferred to semi-solid medium, and IgG positive clones are identified and tested. FITC anti-mouse IgG Fc antibody is used. Positive hybridoma cells are then injected intraperitoneally into mice. Monoclonal antibodies are produced by culturing hybridoma cells in the peritoneal cavity of mice. Hybridoma cells proliferate in the abdomen of mice and produce ascites. This fluid contains a high concentration of antibodies and can be harvested for later use. Antibodies in the ascites are analyzed using GEAKTA TM Protein was purified by protein chromatography (GE Healthcare, Chicago, IL, USA).
[0594] In another experiment, when the desired immune response is achieved, antigen-specific immune cells are isolated from the immunized mice to further obtain anti-CCR8 antibodies or obtain the light chain and heavy chain variable region sequences of anti-CCR8 antibodies. For example, using single cell technology (e.g., using Optofluidic System, Berkeley Lights) to screen and discover plasma cells that secrete antigen-specific monoclonal antibodies, and use reverse transcription and PCR sequencing to obtain antibody variable region sequences. The obtained variable region sequences are used for antibody expression. FACS is used to determine the binding affinity to CCR8.
[0595] In another experiment, phage display was performed to screen and discover antigen-specific monoclonal antibodies.
[0596] Exemplary antibodies obtained by this method include: 11B12, 11F8, and 11F5.
[0597] In another experiment, the "DG" in the VH CDR2 of the antibody described herein is mutated to "SG", "AG" or "DA" to generate a CDR-modified VH. For example, in one embodiment, the "DG" in the VH CDR2 of 11B12 is mutated to "SG", and the resulting CDR-modified VH is named 11B12-SG VH. The sequences of some of these CDR-modified VHs can be found in Figure 4 .
[0598] In another experiment, "DG" in the VL CDR1 of the antibodies described herein was mutated to "SG", "AG", or "DA" to generate CDR-modified VLs. For example, in one embodiment, "DG" in the VL CDR1 of 11B12 was mutated to SG, and the resulting CDR-modified VL was designated 11B12-SG VL. Sequences of a portion of such CDR-modified VLs can be found in Figure 4 .
[0599] In another experiment, "DNS" in the VH framework region of the antibodies described herein was mutated to "DNA" to generate FR-modified VHs. For example, in one embodiment, "DNS" in the VH framework of 11B12 was mutated to "DNA", and the resulting FR-modified VH was designated 11B12-DNA VH. Sequences of a portion of such FR-modified VHs can be found in Figure 4 (e.g., SEQ ID NO:69 - 71). Thus, the antibody has an S74A mutation (Kabat numbering).
[0600] In another experiment, the VH was simultaneously FR-modified (e.g., with DNA) and CDR-modified (e.g., with SG). In one embodiment, "DNS" in the VH framework of 11B12 was mutated to "DNA", and "DG" in the VH CDR2 of 11B12 was mutated to "SG", and the resulting FR-modified and CDR-modified VH was designated 11B12-SG-DNA VH. Sequences of the resulting FR-modified and CDR-modified VH can be found in Figure 4 (e.g., SEQ ID NO:216).
[0601] In another experiment, the amino acid "N" at position 3 in the VH CDR3 of 11F5 was mutated to "S", the amino acid "Y" at position 5 in the VH CDR3 of 11F5 was mutated to "V", and / or the amino acid "Y" at position 6 in the VH CDR3 of 11F5 was mutated to "N" to generate 11F5 CDR3-modified VH. For example, the amino acid "N" at position 3 in the VH CDR3 of 11F5 was mutated to "S", and the resulting CDR-modified VH was named 11F5-N3S VH. The amino acid "Y" at position 5 in the VH CDR3 of 11F5 was mutated to "V", and the resulting CDR-modified VH was named 11F5-Y5V VH. The amino acid "Y" at position 6 in the VH CDR3 of 11F5 was mutated to "N", and the resulting CDR-modified VH was named 11F5-Y6N VH. The amino acid "N" at position 3 and the amino acid "Y" at position 5 in the VH CDR3 of 11F5 were mutated to "S" and "V", respectively, and the resulting CDR-modified VH was named 11F5-N3S-Y5V VH. The amino acid "N" at position 3 and the amino acid "Y" at position 6 in the VH CDR3 of 11F5 were mutated to "S" and "N", respectively, and the resulting CDR-modified VH was named 11F5-N3S-Y6N VH. The amino acid "Y" at position 5 and the amino acid "Y" at position 6 in the VH CDR3 of 11F5 were mutated to "V" and "N", respectively, and the resulting CDR-modified VH was named 11F5-Y5V-Y6N VH. The amino acid "N" at position 3, the amino acid "Y" at position 5, and the amino acid "Y" at position 6 in the VH CDR3 of 11F5 were mutated to "S", "V", and "N", respectively, and the resulting CDR-modified VH was named 11F5-N3S-Y5V-Y6N VH. The sequences of these CDR-modified VH can be found in Figure 4 .
[0602] In another experiment, the VH of the antibody described herein was paired with the VL of another antibody described herein to form an antibody. For example, in one embodiment, the VH of 11B12 was paired with the VL of 11F8, and the resulting antibody was named 11B12-11F8. In one embodiment, the VH of 11B12-SG was paired with the VL of 11F8-SG, and the resulting antibody was named 11B12-SG-11F8-SG. In one embodiment, the VH of 11B12-SG was paired with the VL of 11B12-SG, and the resulting antibody was named 11B12-SG-11B12-SG. In one embodiment, the VH of 11B12-SG-DNA was paired with the VL of 11F8, and the resulting antibody was named 11B12-SG-DNA-11F8. Figure 5 Some publicly available VH and VL combinations are listed. The sequences of the variable regions of the heavy and light chains of these antibodies can be found inFigure 4 。 Figure 2A and Figure 3A show the heavy and light chain CDR sequences of 11B12, 11F8, and 11F5 according to the Kabat definition and the Chothia definition, respectively.
[0603] Various IgG1, IgG2, and IgG4 antibodies were prepared. If the VH and VL of 11B12 are linked to the IgG1 constant region, the antibody is named 11B12. If the VH and VL of 11B12 are linked to the IgG4 constant region, the antibody is named 11B12-IgG4. The constant region can also include some mutations. For example, when the SI mutations (EU numbering: S239D and I332E mutations) are introduced into the Fc region of 11B12, the resulting antibody is named 11B12-SI.
[0604] Example 2. Cross-reactivity of anti-CCR8 antibodies
[0605] CHO-S cells expressing human CCR8 (CHO-S-hCCR8), CHO-S cells expressing mouse CCR8 (CHO-S-mCCR8), HEK293T cells expressing human CCR8 (293T-hCCR8), and HEK293T cells expressing cynomolgus monkey CCR8 (293T-cynCCR8) were seeded in 96-well plates at a density of 5×10 4 cells / well. Diluted sample anti-CCR8 antibody (1 μg / mL) was added to the 96-well plates and incubated at 4 °C for 30 minutes. Subsequently, prior to flow cytometry analysis, the cells were incubated with the secondary antibody anti-hIgG-Fc-Alexa 647 (RL1-H) (Jackson ImmunoResearch Laboratories, catalog number: 109-606-170) at 4 °C and in the dark for 15 minutes.
[0606] CHO-S-hCCR8 cells were obtained by transfecting CHO-S cells with a vector encoding human CCR8 (hCCR8, SEQ ID NO:43). CHO-S-mCCR8 cells were obtained by transfecting CHO-S cells with a vector encoding mouse CCR8 (mCCR8, SEQ ID NO:44). 293T-hCCR8 cells were obtained by transfecting HEK293T cells (ATCC, catalog number: CRL-3216 TM ) with a vector encoding human CCR8. 293T-cynCCR8 cells were obtained by transfecting HEK293T cells with a vector encoding a construct containing the amino acid sequence of cynomolgus monkey CCR8 (cynCCR8, SEQ ID NO:45).
[0607] The test results are shown in the following tables (Table 1 and Table 2). All three anti-CCR8 antibodies can bind to hCCR8, cynCCR8, and mCCR8.
[0608] Table 1. Cross-species binding analysis of anti-CCR8 antibodies
[0609]
[0610] Table 2. Cross-species binding analysis of anti-CCR8 antibodies
[0611]
[0612] Example 3. Cross-binding reactivity of anti-CCR antibodies to CCR8 family proteins
[0613] In each experiment, CHO cells were transfected to express human CCR8 (CHO-S-hCCR8), human CCR2 (hCCR2, SEQ ID NO: 46) (CHO-S-hCCR2), human CCR4 (hCCR4, SEQ ID NO: 47) (CHO-S-hCCR4), human CCR5 (hCCR5, SEQ ID NO: 48) (CHO-S-hCCR5), or human CX3CR1 (hCX3CR1, SEQ ID NO: 49) (CHO-S-hCX3CR1).
[0614] CHO-S-hCCR8, CHO-S-hCCR2, CHO-S-hCCR4, CHO-S-hCCR5, and CHO-S-hCX3CR1 were seeded in 96-well plates at a density of 5×10 4 cells / well. Diluted sample anti-CCR8 antibody (1 μg / mL) was added to the 96-well plates and incubated at 4 °C for 30 minutes. Subsequently, prior to flow cytometry analysis, the cells were incubated with secondary antibody anti-hIgG-Fc-Alexa 647 (RL1-H) (Jackson ImmunoResearch Laboratories, catalog number: 109-606-170) at 4 °C and in the dark for 15 minutes.
[0615] The test results are shown in the following table. None of the three anti-CCR8 antibodies can bind to hCCR2, hCCR4, hCCR5, or hCX3CR1.
[0616] Table 3. Cross-binding reactivity of CCR8 family proteins
[0617]
[0618]
[0619] Plozalizuzumab (MLN1202) is a humanized immunoglobulin G1 (IgG1) anti-CCR2 monoclonal antibody developed by Millennium Pharmaceuticals (Takeda). The VH and VL sequences of the Plozalizuzumab analog are shown in SEQ ID NO:50 and SEQ ID NO:51, respectively.
[0620] Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) anti-CCR4 monoclonal antibody developed by Kyowa Kirin. The VH and VL sequences of the Mogamulizumab analog-SI are shown in SEQ ID NO:52 and SEQ ID NO:53, respectively.
[0621] Leronlimab is a fully humanized IgG4 monoclonal antibody targeting CCR5 developed by CytoDyn. The VH and VL sequences of the Leronlimab analog are shown in SEQ ID NO:54 and SEQ ID NO:55, respectively.
[0622] BII-00313 is a single-chain variable domain (VHH) antibody (VH SEQ ID NO:56) targeting a variant of human CX3C chemokine receptor 1 (CX3CR1) developed by Boehringer Ingelheim. BII-00313-FC-LALA was constructed by linking the BII-00313 variable domain to an IgG1 Fc with LALA mutations (EU numbering: L234A and L235A mutations).
[0623] Example 4. Verification of the binding affinity of anti-CCR8 antibodies 11F5, 11F8, and 11B12
[0624] The binding activities of anti-CCR8 antibodies (11B12, 11F8, 11F5, and 7B16 analogs) to 293T-hCCR8 cells (HEK293T cells expressing human CCR8) or 293T-cynCCR8 (HEK293T cells expressing cynomolgus monkey CCR8) were confirmed by flow cytometry. The secondary antibody used in the experiment was: Alexa 647 anti-human IgG Fcγ (Jackson ImmunoResearch Laboratories, catalog number: 109-606-170). The EC was measured using serially diluted sample anti-CCR8 antibodies 50 . The results are shown in the following table.
[0625] 7B16 is a humanized immunoglobulin G1 (IgG1) anti-CCR8 monoclonal antibody developed by JOUNCE THERAPEUTICS (see WO2021163064A2). The VH and VL sequences of the 7B16 analog are shown in SEQ ID NO:59 and SEQ ID NO:60, respectively.
[0626] Table 4. Affinity test results
[0627]
[0628] The results showed that all three anti-CCR8 antibodies showed binding affinity for human CCR8 and cynomolgus CCR8. Among them, 11B12 bound cynomolgus CCR8 and human CCR8 with similar affinities. Compared with cynomolgus CCR8, 11F8 and 11F5 bound human CCR8 with higher affinities. However, the 7B16 analog showed binding affinity for human CCR8 but no binding affinity for cynomolgus CCR8 (data not shown).
[0629] In another experiment, the binding activities of anti-CCR8 antibodies (11B12, 11F8, 11F5, 10A11 analog, and 7B16 analog) to 293T-hCCR8 cells (HEK293T cells expressing human CCR8) or 293T-mCCR8 (HEK293T cells expressing murine CCR8) were confirmed by flow cytometry. The secondary antibody used in the experiment was PE Goat anti-Human IgG Fc (SouthernBiotech, catalog number: 2014-09). The EC 50 . was determined using serially diluted sample anti-CCR8 antibodies. The results are shown in the following table.
[0630] Table 5. Affinity test results
[0631]
[0632] 10A11 is a humanized immunoglobulin G1 (IgG1) anti-CCR8 monoclonal antibody developed by Shionogi (see WO2020138489A1). The VH and VL sequences of the 10A11 analog are shown in SEQ ID NO:57 and SEQ ID NO:58, respectively.
[0633] The results showed that the anti-CCR8 antibodies 11B12, 11F8, and 11F5 showed good binding affinity for human CCR8 and murine CCR8. The 10A11 analog and 7B16 analog showed binding affinity for human CCR8 but no binding affinity for murine CCR8 (data not shown).
[0634] Example 5. Blocking of calcium flux on cells expressing hCCR8 by anti-hCCR8 monoclonal antibody
[0635] The blocking of the binding of hCCL1 to hCCR8 by human IgG1 anti-CCR8 antibody and CDR-modified and FR-modified anti-CCR8 antibodies was tested by performing a calcium (Ca) flux assay using 293T cells expressing human CCR8. A fluorescence imaging plate reader (FLIPR) Calcium 6 assay kit (Molecular Devices, catalog number: R8190) was used. Cells were seeded one day before the experiment and incubated overnight at 37 °C, 5% CO 2 2. Then the cells were treated with FLIPR Calcium 6 dye (Molecular Devices) containing probenecid (Invitrogen) and PowerLoad (Invitrogen) and incubated at 37 °C for 30 minutes. Different anti-CCR8 monoclonal antibodies were added to the cells and incubation was continued at 37 °C for 30 minutes. After incubation, the fluorescence signal of the Ca flux induced by 1 μg / mL recombinant human CCL1 (BioLegend, catalog number: 582706) was measured for 1 minute using iD3 (Molecular Devices). The results are shown in the table below.
[0636] Table 6. Calcium flux blocking
[0637] Antibody <![CDATA[IC 50 (nM)]]> Maximum inhibition rate (%) 10A11 analog 1.27 68 11B12 2.49 91 11F5 3.98 85 11F8 2.03 99 11B12 - 11F8 3.78 93 11F5 - SG - 11F5 - SG 2.23 90 11F8 - SG - 11F8 - SG 0.77 95 11B12 - SG - 11F8 0.98 99 11B12 - DNA - 11B12 3.28 97
[0638] 11B12, 11F8, 11B12-11F8, 11F8-SG-11F8-SG, 11F5-SG-11F5-SG, 11B12-SG-11F8, and 11B12-DNA-11B12 showed almost complete inhibition. However, the 10A11 analog showed only partial inhibition even at 10 μg / mL.
[0639] Example 6. Biophysical analysis and stability of anti-CCR8 antibodies
[0640] The biophysical properties and stability of three anti-CCR8 antibodies 11B12, 11F8, and 11F5 were evaluated.
[0641] The buffers of the three anti-CCR8 antibodies 11B12, 11F8, and 11F5 were exchanged to pH 6.0 (3 mg / mL histidine, 80 mg / mL sucrose, and 0.2 mg / mL 80). The antibodies were placed in sealed Eppendorf tubes and maintained at 40 ± 2 °C, 60% ± 5% RH (hereinafter referred to as 40 °C) and 4 ± 3 °C (hereinafter referred to as 4 °C) for 14 days, and their thermal stability was evaluated.
[0642] Three anti-CCR8 antibodies, 11B12, 11F8, and 11F5, were loaded onto a Protein A column and eluted with a buffer at pH 3.5 (0.1 mol / L HAc). Immediately, half of the antibody was added to 2 M Tris buffer to adjust the pH to 7.5. The remaining half was maintained at pH 3.5 for 6 hours and then the pH was adjusted to 7.5. The diluted antibody was maintained in a sealed Eppendorf tube at pH 3.5 ± 0.1, 25 ± 2 °C (hereinafter referred to as pH 3.5) for 6 hours to test its stability at low pH.
[0643] The buffers of the three anti-CCR8 antibodies 11B12, 11F8, and 11F5 were exchanged to pH 6.0 (3 mg / mL histidine, 80 mg / mL sucrose, and 0.2 mg / mL 80) and NH 4 HCO 3 stock solution was added to a final concentration of 0.94% NH 4 HCO 3 . The samples were placed in sealed Eppendorf tubes and maintained at 40 ± 2 °C, 60% ± 5% RH for 6 hours (hereinafter referred to as NH 4 HCO 3 6 hours) or 24 hours (hereinafter referred to as NH 4 HCO 3 24 hours) to test their stability.
[0644] Specifically, the following tests were conducted: (1) The purity of the antibody was detected by size exclusion high performance liquid chromatography (SEC-HPLC) (expressed as the percentage of the main peak area in the total area of all peaks (purity, %)); (2) The apparent hydrophobicity of the antibody was detected using hydrophobic interaction chromatography-high performance liquid chromatography (HIC-HPLC) method (expressed as the retention time of the main peak (HIC, min)); (3) The pI (isoelectric point) and charge variants of the antibody were detected by capillary isoelectric focusing (cIEF) method (expressed as the percentages of the main component, acidic component, and basic component); (4) The purity change of the antibody was detected by capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) under non-reducing conditions (CE-SDS(NR)) (expressed as the percentage of the main peak area in the total area of all peaks (purity, %)); (5) The thermodynamic stability of the antibody was detected by a high-throughput multifunctional protein stability analyzer (UNcle, Unchained Labs) (expressed as the melting temperature (Tm) and aggregation temperature (Tagg)).
[0645] In the SEC-HPLC experiment, the antibody sample was diluted to 1 mg / mL with purified water and an Agilent 1290 chromatographic system was used (coupled with an XBridge Protein BEH SEC column ( Waters Corporation) connection). The following parameters were used: Mobile phase: 0.1 M phosphate buffer (PB) + 10% ACN, pH 7.4; Flow rate: 1.8 mL / min; Column temperature: 25 °C; Detection wavelengths: 280 nm, 220 nm; Injection volume: 10 μL; Sample tray temperature: approximately 4 °C; Run time: 7 minutes.
[0646] In the HIC-HPLC experiment, an Agilent 1260 chromatographic system (connected to a ProPac HIC-10 column (4.6×250 mm, Thermo Scientific)) was used, and the sample was diluted 10-fold with mobile phase A. The following parameters were used: Mobile phase A: 0.9 M ammonium sulfate, 0.1 M phosphate buffer (PB), 10% acetonitrile, pH 6.5; Mobile phase B: 0.1 M phosphate buffer (PB), 10% acetonitrile, pH 6.5; Flow rate: 0.8 mL / min; Gradient: 0 minutes 100% A, 2 minutes 100% A, 32 minutes 100% B, 34 minutes 100% B, 35 minutes 100% A, and 45 minutes 100% A; Column temperature: 30 °C; Detection wavelengths: 280 nm, 220 nm; Injection amount: 10 μg; Sample tray temperature: approximately 10 °C; Run time: 50 minutes.
[0647] In the cIEF experiment, Maurice TM cIEF method development kit (ProteinSimple, catalog number: PS-MDK01-C) was used for sample preparation. Specifically, 8 μL, 30 μg protein sample was mixed with the following reagents in the kit: 1 μL Maurice TM cIEF pI marker - 7.05, 1 μL Maurice TM cIEF pI marker - 10.10, 35 μL 1% methylcellulose solution, 2 μL Maurice TM cIEF 500 mM arginine, 1.33 μL ampholyte (Pharmalyte pH range 3 - 10) and 6.66 μL ampholyte (Pharmalyte pH range 8 - 10.5), and water was added to make up the final volume to 100 μL. On the Maurice TM analyzer (ProteinSimple, Santa Clara, CA), using Maurice TM cIEF cassette (PS-MC02-C) to generate imaging capillary isoelectric focusing spectra. The sample was focused for a total of 10 minutes.
[0648] In the CE-SDS experiment, Maurice TM(ProteinSimple, Maurice) and Maurice TM CE-SDS Size Application Kit (ProteinSimple, Catalog No.: PS-MAK02-S).
[0649] In CE-SDS (NR), add 30 μL of sample buffer, 30 μL of 30 μg antibody sample, 1.5 μL of 25× internal standard, and 3 μL of 250 nM iodoacetamide (SIGMA, Catalog No.: 16125) to a microcentrifuge tube. Then centrifuge at 3000 rpm for 1 minute and heat in a 70 °C water bath for 10 minutes. Then cool the sample to room temperature and centrifuge at 10000 rpm for 3 minutes. Then transfer the supernatant sample preparation to a 96-well plate and test on Maurice TM using the following parameters: injection voltage 4.6 kV, injection time 20 seconds, separation voltage 5.75 kV, separation time 40 minutes.
[0650] In the UNcle experiment, load 8 μL of protein sample into a Uni-tube, and the system runs at a heating rate of 1 °C / min at a thermal temperature from 25 °C to 95 °C. Detect the particle size and polydispersity by dynamic light scattering (DLS) before heating. Characterize the protein stability by differential scanning full-spectrum fluorescence (DSF), static light scattering (SLS), and dynamic light scattering (DLS).
[0651] The detailed results of 11B12, 11F8, and 11F5 are shown in the following table. The results show that 11B12, 11F8, and 11F5 exhibit good stability and biophysical properties.
[0652] Table 7. Test Results of Biophysical Properties
[0653]
[0654] Table 8. Stability of Anti-CCR8 Antibodies
[0655]
[0656] Example 7. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Assay
[0657] In the reporter gene assay (ADCC reporter gene assay), use engineered Jurkat cells as effector cells (Jurkat-Luc-hCD16A-158V), and use H293T cells with hCCR8 surface antigen as target cells. Incubate each antibody with the cells (4:1) for 6 hours to measure ADCC activity. The results are shown below.
[0658] Table 9. ADCC Assay
[0659] Antibody <![CDATA[EC 50 (μg / mL)]]> 7B16 analog - SI 0.0038 11B12 - SI 0.0016 11F5 - SI 0.0039 11F8 - SI 0.0059 7B16 analog 0.0178 11B12 0.0130 11F5 0.0084 11F8 0.0191
[0660] The results showed that all anti-CCR8 antibodies had ADCC activity comparable to that of the positive control drug (7B16 analog), and the SI mutation led to stronger ADCC activity compared to the wild type (WT).
[0661] In another experiment, the ADCC activities of human IgG1 anti-CCR8 antibodies and CDR-modified and FR-modified anti-CCR8 antibodies were measured. The results are shown in the following table.
[0662] The results showed that anti-CCR8 antibodies 11B12-11F8, 11F5-SG-11F5-SG, 11F8-SG-11F8-SG, 11B12-SG-11F8, and 11B12-DNA-11B12 had ADCC activity. Among them, 11B12-11F8, 11F5-SG-11F5-SG, 11F8-SG-11F8-SG, and 11B12-SG-11F8 showed better ADCC activity compared to 11B12, 11F5, and 11F8.
[0663] Table 10. ADCC assay
[0664] Antibody <![CDATA[EC 50 (μg / mL)]]> 11B12 - 11F8 0.0075 11F5 - SG - 11F5 - SG 0.0055 11F8 - SG - 11F8 - SG 0.0044 11B12 - SG - 11F8 0.0075 11B12 - DNA - 11B12 0.0162
[0665] Example 8. Antitumor activity of anti-CCR8 antibodies
[0666] The effect of anti-CCR8 antibodies on tumor growth in vivo was tested in a colon cancer model. Each B-hCCR8 mouse (Beijing Biocytogen Co., Ltd., Beijing, China; catalog number: 110096) was subcutaneously injected with approximately 5×10 5 MC38 cells (murine colon cancer cells). When the tumor volume in the mice reached approximately 100 mm 3 , the mice were randomly divided into different groups according to the tumor volume. Then, the mice were given phosphate-buffered saline (PBS) or anti-human CCR8 antibody by intraperitoneal injection.
[0667] The injection volume was calculated based on the body weight of the mice and the required dose of 10 mg / kg. The lengths of the major and minor axes of the tumors were measured, and the tumor volume was calculated as 0.5×(major axis)×(minor axis) 2
[0668] The percentage of tumor growth inhibition (TGI%) was calculated using the following formula: TGI(%) = [1 - (Ti - T0) / (Vi - V0)] × 100. Ti is the average tumor volume in the treatment group on day i. T0 is the average tumor volume in the treatment group on day 0. Vi is the average tumor volume in the control group on day i. V0 is the average tumor volume in the control group on day 0.
[0669] Values are expressed as mean ± SEM. Statistical analysis was performed using a t-test. A TGI% higher than 60% indicates significant inhibition of tumor growth. P < 0.05 is the threshold indicating significant difference.
[0670] Table 11. Experimental groups
[0671] Group Number of mice Antibody Dose Route Frequency Total number of administrations G1 6 PBS - i.p. BIW 6 G2 6 10A11 analog 10 mg / kg i.p. BIW 6 G3 6 7B16 analog 10 mg / kg i.p. BIW 6 G4 6 11F5 10 mg / kg i.p. BIW 6
[0672] The body weights of the mice in different groups all increased. On the day of grouping (day 0), the average body weight of each group was in the range of 19.8 g - 20.3 g. At the end of the experiment (day 21), the average body weight of each group was in the range of 21.6 g - 24.6 g. The change in the average body weight of each group was in the range of 111.4% - 121.8%. The results showed that the tested antibody was well tolerated and had no obvious toxicity to the mice.
[0673] The tumor sizes in the group treated with anti-CCR8 antibody were as Figure 1 shown. The following table summarizes the results of this experiment, including the tumor volumes on the day of grouping (day 0), 7 days after grouping (day 7), 14 days after grouping (day 14), and at the end of the experiment (day 21); the survival rate of the mice; the tumor growth inhibition value (TGI); and the statistical differences (P values) in tumor volume and body weight between the treatment group and the control group.
[0674] The results showed that 11F5 exhibited better tumor growth inhibition effects than the positive control 10A11 analog and 7B16 analog.
[0675] Table 12. Changes in tumor size
[0676]
[0677] In other similar experiments, the effects of anti-CCR8 antibodies 11F5, 11F5-SI, and / or 11F8-SI on in vivo tumor growth were tested at a dose of 3 mg / kg in a colon cancer model.
[0678] Tables 13 and 14 summarize the tumor volumes on the day of grouping (day 0), 14 days after grouping (day 14), and 21 days after grouping (day 21); the tumor growth inhibition values (TGI); and the statistical differences (P values) in tumor volume and body weight between the treatment group and the control group in two different experiments.
[0679] Table 13. Changes in Tumor Size
[0680]
[0681]
[0682] Table 14. Changes in Tumor Size
[0683]
[0684] The results showed that 11F5, 11F5-SI, and 11F8-SI showed good tumor growth inhibitory effects in colon cancer, and 11F5-SI showed a better tumor growth inhibitory effect than 11F5.
[0685] In addition, in another experiment, the effects of 11F8-SI and 11B12-SI on tumor growth were also tested in a colon cancer model. B-hPD-1 / hPD-L1 / hCCR8 mice (Beijing Biocytogen Co., Ltd., Beijing, China; catalog number: 131764) were subcutaneously injected with approximately 5×10 5 MC38 cells. When the tumor volume in the mice reached approximately 100 - 150 mm 3 , the mice were randomly divided into different groups (6 mice per group) according to the tumor volume. Then, the mice were given PBS (G1, control), 3 mg / kg 11F8-SI (G2), and 3 mg / kg 11B12-SI (G3) by intraperitoneal injection. The antibodies were administered on the first and fourth days of each week for 3 weeks (a total of 6 injections).
[0686] The results showed that 11F8-SI and 11B12-SI showed good tumor growth inhibitory effects, with TGI% being 44.34% and 37.60% respectively.
[0687] Example 9. Verification of the Binding Affinity of Anti-CCR8 Antibodies
[0688] The binding activity of the anti-CCR8 antibody to 293T-hCCR8 cells (obtained by transfecting HEK293T cells to express human CCR8) and 293T-mCCR8 cells (HEK293T cells expressing murine CCR8) was verified by flow cytometry. The secondary antibody used in the experiment was PE Goat anti-Human IgG Fc (SouthernBiotech, catalog number: 2014-09). The EC was determined using serially diluted sample anti-CCR8 antibody 50 . The results are shown in the following table
[0689] Table 15. Affinity test results
[0690]
[0691]
[0692] In other experiments, the binding activities of CDR-modified anti-CCR8 antibody and FR-modified anti-CCR8 antibody to 293T-hCCR8 cells and 293T-mCCR8 were verified by flow cytometry. The results are shown in the following table
[0693] Table 16. Affinity test results
[0694]
[0695] (“—” indicates that EC was not calculated 50 )
[0696] Example 10. Epitope analysis of anti-hCCR8 antibody
[0697] To analyze the amino acid residues involved in the binding activity of anti-hCCR8 antibodies to human CCR8, human CCR8 point mutants were prepared with amino acids in their extracellular domains (N-terminus, ECL1, ECL2, and ECL3), and then the binding activities of 11F5, 11F8, 11F8-SG-11F8-SG, 11B12-11F8, and 11B12-SG-11F8 to the mutants were evaluated by flow cytometry. The analysis showed that multiple amino acids in each extracellular domain (N-terminus, ECL1, ECL2, and ECL3) were involved in the binding activity of the clones. In particular, significant decreases in clone binding activity were observed in the Y17A (Y at position 17 of human CCR8 (SEQ ID NO: 43) was replaced with A, and the same applies hereinafter), F21A, D97A, W99A, F101A, G102A, C106A, G179A, C183A, W194A, K195A, I196A, and L278A mutants. F at position 21 is conserved between human and mouse CCR8. Binding to F21 may be very important for demonstrating cross-reactivity with mouse CCR8. The F21A mutant did not alter the binding activities of the 10A11 analogue and the 7B16 analogue. This may explain why these clones do not cross-react with mouse CCR8.
[0698] Example 11. Combination Therapy with Anti-PD-1 Antibodies
[0699] To evaluate the effectiveness of the combination therapy, anti-CCR8 antibodies were administered to mice together with another therapeutic agent, a Pembrolizumab analogue.
[0700] The Pembrolizumab analogue is a humanized immunoglobulin G1 (IgG1) anti-PD-1 monoclonal antibody. The VH and VL sequences of the Pembrolizumab analogue are shown as SEQ ID NO: 217 and SEQ ID NO: 218, respectively.
[0701] B-hPD-1 / hPD-L1 / hCCR8 mice (Beijing Biocytogen Co., Ltd., Beijing, China; catalog number: 131764) were subcutaneously injected with approximately 5×10 5 MC38 cells (murine colon cancer cells). When the tumor volume in the mice reached approximately 100 - 150 mm 3When the time came, the mice were randomly divided into different groups (6 mice per group) according to tumor volume. Then, the mice were given PBS (G1, control), 0.3 mg / kg Pembrolizumab analog (G2), 3 mg / kg 11F5 (G3), and a combination of 0.3 mg / kg Pembrolizumab analog and 3 mg / kg 11F5 (G4) by intraperitoneal injection. The antibodies were administered on the first and fourth days of each week for 3 weeks (a total of 6 injections).
[0702] The body weights of the mice were monitored throughout the treatment period. The body weights of the mice in different groups all increased. On the day of grouping (day 0), the average weight of each group was in the range of 18.2 g - 19.2 g; at the end of the experiment (day 28), the average weight of each group was in the range of 21.7 g - 23.5 g, and the change in the average weight of each group was in the range of 114.4% - 123.3%. The results showed that the tested antibodies were well tolerated and had no obvious toxicity to the mice.
[0703] The following table summarizes the results of this experiment, including the tumor volume on the day of grouping (day 0), 14 days after grouping (day 14), and at the end of the experiment (day 28); the survival rate of the mice; the tumor growth inhibition value (TGI); and the statistical differences (P values) in tumor volume and body weight between the treatment group and the control group.
[0704] Table 17. Changes in tumor size
[0705]
[0706] The tumor sizes of each treatment group were also as Figure 6 shown. The results showed that compared with the control group (G1), the treatment groups (G2 - G4) showed different anti-tumor effects. In addition, the combination of 11F5 and Pembrolizumab analog (G4) inhibited tumor growth with a higher TGI% than 11F5 (G3) or Pembrolizumab analog (G2).
[0707] In another similar experiment, the effects of the combination of 11F5 - SI and Pembrolizumab analog or the combination of 11B12 - SI and Pembrolizumab analog on in vivo tumor growth were tested in a colon cancer model to evaluate the effectiveness of combination therapy. The details are shown in the following table.
[0708] Table 18. Experimental grouping
[0709]
[0710] The tumor sizes of each treatment group were as Figure 7As shown, the combination therapy of 11F5-SI and the Pembrolizumab analogue (G4) inhibited tumor growth with a significantly higher TGI% (77.49%) than that of 11F5-SI (G3) or the Pembrolizumab analogue (G2). Similarly, the combination therapy of 11B12-SI and the Pembrolizumab analogue (G6) inhibited tumor growth with a significantly higher TGI% (74.52%) than that of 11B12-SI (G5) or the Pembrolizumab analogue (G2).
[0711] Example 12. Verification of the binding affinity of 11F5 and its CDR3-modified antibodies
[0712] The binding activities of 11F5 and its CDR3-modified antibodies to 293T-hCCR8 cells and 293T-mCCR8 cells were verified by flow cytometry. The secondary antibody used in the experiment was PE Goat anti-human IgG Fc (SouthernBiotech, catalog number: 2014-09). The EC was measured using serially diluted sample antibodies 50 . The results are shown in the following table.
[0713] Table 19. Results of the affinity test
[0714]
[0715] The results showed that the anti-CCR8 antibody 11F5 and its CDR3-modified antibodies could bind to human CCR8 and mouse CCR8 with high affinity.
[0716] Example 13. Determination of the antibody-dependent cell cytotoxicity (ADCC) of 11F5 and its CDR3-modified antibodies
[0717] The ADCC activities of 11F5 and its CDR3-modified antibodies were measured. The results are shown in the following table.
[0718] Specifically, engineered Jurkat cells were used as effector cells (Jurkat-Luc-hCD16A-158V), and H293T cells with the hCCR8 surface antigen were used as target cells. The cells were incubated with each antibody at a ratio of 4:1 for 6 hours to measure the ADCC activity. The results are shown in the following table.
[0719] Table 20. ADCC activities
[0720] Antibody <![CDATA[EC 50 (μg / mL)]]> 11F5 0.0108 11F5 - N3S - 11F5 0.0057 11F5 - Y5V - 11F5 0.0296 11F5 - Y6N - 11F5 0.0099 11F5 - N3S - Y5V - 11F5 0.0073 11F5 - N3S - Y6N - 11F5 0.0064 11F5 - Y5V - Y6N - 11F5 0.0362 11F5 - N3S - Y5V - Y6N - 11F5 0.0080
[0721] The results showed that 11F5 and all CDR3-modified antibodies exhibited strong ADCC activities.
[0722] In another similar experiment, 11F5 with SI mutations in the Fc region and its CDR3-modified antibodies were also assayed. The results are shown in the following table, indicating that when SI mutations were introduced into the Fc region, 11F5 and its CDR3-modified antibodies showed stronger ADCC activity.
[0723] Table 21. ADCC Activity
[0724] Antibody <![CDATA[EC 50 (μg / mL)]]> 11F5 - SI 0.0022 11F5 - N3S - 11F5 - SI 0.0007 11F5 - N3S - Y5V - 11F5 - SI 0.0014 11F5 - N3S - Y6N - 11F5 - SI 0.0017 11F5 - N3S - Y5V - Y6N - 11F5 - SI 0.0011 11F5 0.0337 11F5 - N3S - 11F5 0.0173 11F5 - N3S - Y5V - 11F5 0.0124 11F5 - N3S - Y6N - 11F5 0.0107 11F5 - N3S - Y5V - Y6N - 11F5 0.0102
[0725] Example 14. Biophysical Analysis and Stability of 11F5 and / or Its CDR3-Modified Antibodies
[0726] The biophysical properties of 11F5 and its CDR3-modified antibodies were evaluated. Similar experiments as described in Example 6 were employed. Additionally, colloidal stability was detected using upright single-layer chromatography (SMAC) (expressed as the retention time of the main peak (SMAC, min)), and cross-interaction with human serum polyclonal antibodies was detected using cross-interaction chromatography (CIC) (expressed as the retention time of the main peak (CIC, min)).
[0727] In the SAMC experiment, an Agilent 1260 chromatographic system (connected to a Zenix TM column (4.6 mm × 30 cm, Sepax, catalog number: 213300-4630)) was used, and the sample was diluted to 1 mg / mL with PBS. The following parameters were used: mobile phase: 150 mM sodium phosphate (pH 7.0); flow rate: 0.35 mL / min; column temperature: 30 °C; detection wavelengths: 280 nm, 220 nm; run time: 25 minutes; injection mass: 2 μg.
[0728] In the CIC experiment, an Agilent 1260 chromatographic system coupled with human serum polyclonal antibodies (Sigma, catalog number: I4506) (connected to a 1 mL (GE Healthcare, catalog number: 17-0716-01)) was used, and the sample was diluted to 1 mg / mL with PBS. The following parameters were used: mobile phase: PBS (pH 7.2 - 7.4); flow rate: 0.1 mL / min; detection wavelengths: 280 nm, 220 nm; run time: 50 minutes; injection mass: 10 μg.
[0729] Table 22. Test Results of Biophysical Properties
[0730]
[0731] The results showed that these CDR3-modified antibodies of 11F5 exhibited good biophysical properties.
[0732] In another experiment, the stabilities of 11F5-N3S-Y5V-11F5-SI and 11F5-N3S-Y5V-Y6N-11F5-SI were evaluated. The results are shown in the following table. Both 11F5-N3S-Y5V-11F5-SI and 11F5-N3S-Y5V-Y6N-11F5-SI showed good stability.
[0733] Table 23. Stability of antibodies with CDR3 modification of 11F5
[0734]
[0735] Example 15. 11F5 and its antibodies with CDR3 modification block calcium flux on cells expressing hCCR8
[0736] The blocking of the binding of hCCL1 to hCCR8 by 11F5 and its antibodies with CDR3 modification was tested by performing a calcium (Ca) flux assay using 293T cells expressing human CCR8. The FLIPR Calcium 6 Assay Kit (Molecular Devices, catalog number: R8190) was used. Cells were seeded one day before the experiment and incubated overnight at 37 °C, 5% CO 2 2. Then they were treated with FLIPR Calcium 6 Dye (Molecular Devices) containing probenecid (Invitrogen) and PowerLoad (Invitrogen) and incubated at 37 °C for 30 minutes. Anti-CCR8 antibodies were added to the cells and incubation was continued at 37 °C for 30 minutes. After incubation, the fluorescence signal of the Ca flux induced by 1 μg / mL recombinant human CCL1 (BioLegend, catalog number: 582706) was measured for 1 minute using iD3 (Molecular Devices). The results are as Figure 8 shown in the following table.
[0737] Table 24. Calcium flux blocking
[0738] Antibody <![CDATA[IC 50 (nM)]]> Maximum inhibition rate (%) 11F5 5.573 82 11F5 - N3S - 11F5 0.787 93 11F5 - Y6N - 11F5 1.314 74 11F5 - N3S - Y5V - 11F5 2.533 96 11F5 - N3S - Y5V - Y6N - 11F5 2.898 85
[0739] The results showed that in the calcium influx blocking experiment, the antibodies with CDR3 modification of 11F5, namely 11F5-N3S-11F5, 11F5-Y6N-11F5, 11F5-N3S-Y5V-11F5, and 11F5-N3S-Y5V-Y6N-11F5, all showed better blocking activity than 11F5. In particular, 11F5-N3S-Y5V-11F5 showed almost complete inhibition.
[0740] Example 16. Antitumor activity of 11F5 and its antibodies with CDR3 modification
[0741] The effects of 11F5 and its CDR3-modified antibodies on tumor growth in vivo were tested in a colon cancer model. Approximately 5×10 5 MC38 cells were subcutaneously injected into each B-hCCR8 mouse. When the tumor volume in the mice reached approximately 150 mm 3 , the mice were randomly divided into different groups according to the tumor volume. Then, the mice were given phosphate-buffered saline (PBS), 11F5, or its CDR3-modified antibody by intraperitoneal injection.
[0742] The injection volume was calculated based on the body weight of the mice and the required dose of 3 mg / kg (details are shown in the following table).
[0743] Table 25. Experimental groups
[0744] Group Number of mice Antibody Dose Route Frequency Total number of administrations G1 6 PBS - i.p. BIW 6 G2 6 11F5 - N3S - Y5V - 11F5 - SI 3 mg / kg i.p. BIW 6 G3 6 11F5 - SI 3 mg / kg i.p. BIW 6
[0745] The following table summarizes the results of this experiment, including the tumor volume on the day of grouping (day 0), 14 days after grouping (day 14), and 21 days of the experiment (day 21); the survival rate of the mice; the tumor growth inhibition value (TGI); and the statistical differences (P values) in tumor volume and body weight between the treatment group and the control group.
[0746] Table 26. Changes in tumor size
[0747]
[0748] The results showed that 11F5-N3S-Y5V-11F5-SI exhibited better tumor growth inhibition effects than 11F5-SI.
[0749] Other embodiments
[0750] It should be understood that although the present invention has been described in connection with specific embodiments of the present invention, the foregoing description is intended to illustrate rather than limit the scope of the present invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims
1. An antibody or antigen-binding fragment thereof that binds to CCR8 (chemokine (C-C motif) receptor 8), said antibody or antigen-binding fragment comprising: a heavy-chain variable region (VH) comprising complementarity-determining regions (CDR) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR3 amino acid sequence; and a light-chain variable region (VL) comprising CDR 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR3 amino acid sequence, wherein the selected VH CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:1, 2, 3, respectively, (2) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:4, 5, 6, respectively; (3) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:7, 8, 9, respectively; (4) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:10, 11, 12, respectively; (5) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:13, 14, 15, respectively; (6) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:16, 17, 18, respectively; (7) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:72, 73, 74, respectively; (8) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:75, 76, 77, respectively; (9) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:78, 79, 80, respectively; (10) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:81, 82, 83, respectively; (11) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:84, 85, 86, respectively; (12) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:87, 88, 89, respectively; (13) The selected VH CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:90, 91, 92, respectively; (14) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 93, 94, and 95, respectively; (15) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 96, 97, and 98, respectively; (16) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 144, 145, and 146, respectively; (17) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 147, 148, and 149, respectively; (18) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 150, 151, and 152, respectively; (19) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 153, 154, and 155, respectively; (20) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 156, 157, and 158, respectively; (21) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 159, 160, and 161, respectively; (22) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 162, 163, and 164, respectively; (23) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 165, 166, and 167, respectively; (24) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 168, 169, and 170, respectively; (25) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 219, 220, and 221, respectively; (26) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 222, 223, and 224, respectively; (27) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 225, 226, and 227, respectively; (28) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 228, 229, and 230, respectively; (29) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 231, 232, and 233, respectively; (30) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 234, 235, and 236, respectively; (31) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 237, 238, and 239, respectively; (32) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 240, 241, and 242, respectively; (33) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 243, 244, and 245, respectively; (34) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 246, 247, and 248 respectively; (35) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 249, 250, and 251 respectively; (36) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 252, 253, and 254 respectively; (37) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 255, 256, and 257 respectively; and (38) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 258, 259, and 260 respectively; wherein the selected VL CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 19, 20, and 21 respectively; (2) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 22, 23, and 24 respectively; (3) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 25, 26, and 27 respectively; (4) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 28, 29, and 30 respectively; (5) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 31, 32, and 33 respectively; (6) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 34, 35, and 36 respectively; (7) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 108, 109, and 110 respectively; (8) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 111, 112, and 113 respectively; (9) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 114, 115, and 116 respectively; (10) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 117, 118, and 119 respectively; (11) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 120, 121, and 122 respectively; (12) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 123, 124, and 125 respectively; (13) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 126, 127, and 128 respectively; (14) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO: 129, 130, and 131 respectively; (15) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:132, 133, and 134, respectively; (16) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:180, 181, and 182, respectively; (17) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:183, 184, and 185, respectively; (18) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:186, 187, and 188, respectively; (19) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:189, 190, and 191, respectively; (20) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:192, 193, and 194, respectively; (21) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:195, 196, and 197, respectively; (22) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:198, 199, and 200, respectively; (23) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:201, 202, and 203 respectively; and (24) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:204, 205, and 206, respectively.
2. An antibody or antigen-binding fragment thereof that binds to CCR8 (chemokine (C-C motif) receptor 8), said antibody or antigen-binding fragment comprising: a heavy chain variable region (VH) comprising complementarity-determining regions (CDR) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence having at least 80% identity to a selected VH CDR3 amino acid sequence; and a light chain variable region (VL) comprising CDR1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence having at least 80% identity to a selected VL CDR3 amino acid sequence, wherein the selected VH CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VH CDR1 is SYVMH (SEQ ID NO:99); the selected VH CDR2 is VISYX 1 X 2 SDKYYADSVKG (SEQ ID NO:100); the selected VH CDR3 is GRGYRYGQSYYYGMDV (SEQ ID NO:101); (2) The selected VH CDR1 is SYVVH (SEQ ID NO: 102); the selected VH CDR2 is VISYX 1 X 2 DNKFYADSVKG (SEQ ID NO: 103); the selected VH CDR3 is GRX 5 YX 6 X 7 YYGLDV (SEQ ID NO: 104); (3) The selected VH CDR1 is TYVMH (SEQ ID NO:105); the selected VH CDR2 is VISYX 1 X 2 NNKYYADSVKG (SEQ ID NO:106); the selected VH CDR3 is GRSYVNYYGLDV (SEQ ID NO:107); (4) The selected VH CDR1 is GFSFSSY (SEQ ID NO:171); the selected VH CDR2 is SYX 1 X 2 SD (SEQ ID NO:172); the selected VH CDR3 is GRGYRYGQSYYYGMDV (SEQ ID NO:173); (5) The selected VH CDR1 is GFTFSSY (SEQ ID NO: 174); the selected VH CDR2 is SYX 1 X 2 DN (SEQ ID NO: 175); the selected VH CDR3 is GRX 5 YX 6 X 7 YYGLDV (SEQ ID NO: 176); and (6) The selected VH CDR1 is GFTFSTY (SEQ ID NO:177); the selected VH CDR2 is SYX 1 X 2 NN (SEQ IDNO:178); the selected VH CDR3 is GRSYVNYYGLDV (SEQ ID NO:179); wherein the selected VL CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:135); the selected VL CDR2 is EVSNRFS (SEQ ID NO:136); the selected VL CDR3 is MQSIKLPLT (SEQ ID NO:137); (2) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:138); the selected VL CDR2 is EVSNRFS (SEQ ID NO:139); the selected VL CDR3 is MQSLKVPPT (SEQ ID NO:140); (3) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:141); the selected VL CDR2 is EVSNRFS (SEQ ID NO:142); the selected VL CDR3 is MQSVKIPLT (SEQ ID NO:143); (4) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:207); the selected VL CDR2 is EVSNRFS (SEQ ID NO:208); the selected VL CDR3 is MQSIKLPLT (SEQ ID NO:209); (5) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:210); the selected VL CDR2 is EVSNRFS (SEQ ID NO:211); the selected VL CDR3 is MQSLKVPPT (SEQ ID NO:212); and (6) The selected VL CDR1 is KSSQSLLYSX 3 X 4 KTYLY (SEQ ID NO:213); the selected VL CDR2 is EVSNRFS (SEQ ID NO:214); the selected VL CDR3 is MQSVKIPLT (SEQ ID NO:215); wherein X in each sequence 1 and X 3 are independently selected from the group consisting of D, S, and A wherein X in each of the sequences 2 and X 4 are independently selected from the group consisting of G and A, wherein X in SEQ ID NO: 104 or 176 5 is independently selected from the group consisting of N and S, wherein X in SEQ ID NO: 104 or 176 6 is independently selected from the group consisting of Y and V, wherein X in SEQ ID NO: 104 or 176 7 is independently selected from the group consisting of Y and N.
3. The antibody or antigen-binding fragment thereof according to claim 1, wherein the selected VH CDR1, 2, and 3 amino acid sequences and the selected VL CDR1, 2, and 3 amino acid sequences are one of the following: (1) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 1, 2, and 3, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 19, 20, and 21, respectively; (2) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 4, 5, and 6, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (3) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 7, 8, and 9, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 25, 26, and 27, respectively; (4) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 10, 11, and 12, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 28, 29, and 30, respectively; (5) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 13, 14, and 15, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively; (6) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 16, 17, and 18, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 34, 35, and 36, respectively; (7) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 1, 2, and 3, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (8) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 1, 2, and 3, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 25, 26, and 27, respectively; (9) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 4, 5, and 6, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 19, 20, and 21, respectively; (10) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 4, 5, and 6, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 25, 26, and 27, respectively; (11) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 7, 8, and 9, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 19, 20, and 21, respectively; (12) According to the Kabat definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 7, 8, and 9, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (13) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 10, 11, and 12, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively; (14) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 10, 11, and 12, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 34, 35, and 36, respectively; (15) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 13, 14, and 15, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 28, 29, and 30, respectively; (16) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 13, 14, and 15, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 34, 35, and 36, respectively; (17) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 16, 17, and 18, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 28, 29, and 30, respectively; and (18) According to the Chothia definition, the VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 16, 17, and 18, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33 shown, respectively.
4. The antibody or antigen-binding fragment thereof according to claim 1, wherein the selected VH CDR1, 2, and 3 amino acid sequences and the selected VL CDR1, 2, and 3 amino acid sequences are one of the following: (1) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 1, 2, and 3, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 114, 115, and 116, respectively; (2) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 72, 73, and 74, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 114, 115, and 116, respectively; (3) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 72, 73, and 74, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 108, 109, and 110, respectively; (4) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 78, 79, and 80, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 114, 115, and 116, respectively; (5) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 75, 76, and 77, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 111, 112, and 113, respectively; (6) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 10, 11, and 12, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 186, 187, and 188, respectively; (7) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 144, 145, and 146, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 186, 187, and 188, respectively; (8) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 144, 145, and 146, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 180, 181, and 182, respectively; (9) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 150, 151, and 152, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 186, 187, and 188, respectively; (10) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 147, 148, and 149, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 183, 184, and 185, respectively; (11) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 72, 73, and 74, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 25, 26, and 27, respectively; (12) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 144, 145, and 146, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 34, 35, and 36, respectively; (13) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 219, 220, and 221, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (14) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 222, 223, and 224, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (15) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 225, 226, and 227, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (16) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 228, 229, and 230, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (17) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 231, 232, and 233, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (18) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 234, 235, and 236, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (19) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 237, 238, and 239, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 22, 23, and 24, respectively; (20) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 240, 241, and 242, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively; (21) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 243, 244, and 245, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively; (22) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 246, 247, and 248, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively; (23) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 249, 250, and 251, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively; (24) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 252, 253, and 254, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively; (25) The VH comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 255, 256, and 257, respectively, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively; and (26) The VH includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 258, 259, and 260, respectively, and the VL includes CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 31, 32, and 33, respectively.
5. The antibody or antigen-binding fragment thereof according to any one of claims 1-4, wherein the antibody or antigen-binding fragment specifically binds to human CCR8, mouse CCR8, or monkey CCR8.
6. The antibody or antigen-binding fragment thereof according to any one of claims 1-5, wherein the antibody or antigen-binding fragment is a human or humanized antibody or antigen-binding fragment thereof (such as a human IgG1 antibody).
7. The antibody or antigen-binding fragment thereof according to any one of claims 1-6, wherein the antibody or antigen-binding fragment is a single-chain variable fragment (scFv), a single-arm antibody, or a multispecific antibody (such as a bispecific antibody).
8. A nucleic acid comprising a polynucleotide encoding a polypeptide, the polypeptide comprising: an immunoglobulin heavy chain or fragment thereof containing a heavy chain variable region (VH), the VH including complementarity-determining regions (CDR) 1, 2, and 3, and wherein the VH binds to CCR8 when paired with a light chain variable region (VL), wherein the VH CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1, 2, and 3, respectively, (2) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 4, 5, and 6, respectively; (3) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 7, 8, and 9, respectively; (4) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 10, 11, and 12, respectively; (5) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 13, 14, and 15, respectively; (6) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 16, 17, and 18, respectively; (7) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 72, 73, and 74, respectively; (8) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 75, 76, and 77, respectively; (9) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 78, 79, and 80, respectively; (10) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 81, 82, and 83, respectively; (11) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 84, 85, and 86, respectively; (12) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 87, 88, and 89, respectively; (13) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:90, 91, and 92 respectively; (14) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:93, 94, and 95 respectively; (15) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:96, 97, and 98 respectively; (16) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:99, 100, and 101 respectively; (17) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:102, 103, and 104 respectively; (18) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:105, 106, and 107 respectively; (19) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:144, 145, and 146 respectively; (20) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:147, 148, and 149 respectively; (21) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:150, 151, and 152 respectively; (22) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:153, 154, and 155 respectively; (23) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:156, 157, and 158 respectively; (24) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:159, 160, and 161 respectively; (25) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:162, 163, and 164 respectively; (26) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:165, 166, and 167 respectively; (27) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:168, 169, and 170 respectively; (28) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:171, 172, and 173 respectively; (29) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:174, 175, and 176 respectively; (30) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:177, 178, and 179 respectively; (31) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:219, 220, and 221 respectively; (32) The selected VH CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:222, 223, and 224 respectively; (33) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 225, 226, and 227, respectively; (34) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 228, 229, and 230, respectively; (35) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 231, 232, and 233, respectively; (36) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 234, 235, and 236, respectively; (37) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 237, 238, and 239, respectively; (38) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 240, 241, and 242, respectively; (39) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 243, 244, and 245, respectively; (40) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 246, 247, and 248, respectively; (41) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 249, 250, and 251, respectively; (42) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 252, 253, and 254, respectively; (43) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 255, 256, and 257, respectively; and (44) The selected VH CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 258, 259, and 260, respectively; wherein the VL amino acid sequence is selected from the group consisting of SEQ ID NO: 40, 41, 42, 66, 67, and 68.
9. The nucleic acid according to claim 8, wherein the nucleic acid comprises a polynucleotide encoding a polypeptide, the polypeptide comprising an immunoglobulin heavy chain containing VH or a fragment thereof, and the VH comprises CDR1, 2, and 3 having amino acid sequences shown in SEQ ID NO: 1, 2, and 3, respectively.
10. The nucleic acid according to claim 8, wherein the nucleic acid comprises a polynucleotide encoding a polypeptide, the polypeptide comprising an immunoglobulin heavy chain containing VH or a fragment thereof, and the VH comprises CDR1, 2, and 3 having amino acid sequences shown in SEQ ID NO: 4, 5, and 6, respectively.
11. The nucleic acid according to claim 8, wherein the nucleic acid comprises a polynucleotide encoding a polypeptide, the polypeptide comprising an immunoglobulin heavy chain containing VH or a fragment thereof, and the VH comprises CDR1, 2, and 3 having amino acid sequences shown in SEQ ID NO: 7, 8, and 9, respectively.
12. A nucleic acid comprising a polynucleotide encoding a polypeptide, the polypeptide comprising: An immunoglobulin heavy chain or a fragment thereof containing a variable light chain (VL), said VL comprising complementarity determining regions (CDRs) 1, 2, and 3, and wherein said VL binds to CCR8 when paired with a variable heavy chain (VH), wherein the selected VL CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:19, 20, 21, respectively; (2) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:22, 23, 24, respectively; (3) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:25, 26, 27, respectively; (4) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:28, 29, 30, respectively; (5) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:31, 32, 33, respectively; (6) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:34, 35, 36, respectively; (7) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:108, 109, 110, respectively; (8) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:111, 112, 113, respectively; (9) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:114, 115, 116, respectively; (10) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:117, 118, 119, respectively; (11) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:120, 121, 122, respectively; (12) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:123, 124, 125, respectively; (13) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:126, 127, 128, respectively; (14) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:129, 130, 131, respectively; (15) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:132, 133, 134, respectively; (16) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:135, 136, 137, respectively; (17) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:138, 139, 140, respectively; (18) The selected VL CDR1, 2, 3 amino acid sequences are shown as SEQ ID NO:141, 142, 143, respectively; (19) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:180, 181, and 182, respectively; (20) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:183, 184, and 185, respectively; (21) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:186, 187, and 188, respectively; (22) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:189, 190, and 191, respectively; (23) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:192, 193, and 194, respectively; (24) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:195, 196, and 197, respectively; (25) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:198, 199, and 200, respectively; (26) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:201, 202, and 203, respectively; (27) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:204, 205, and 206, respectively; (28) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:207, 208, and 209, respectively; (29) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:210, 211, and 212, respectively; and (30) The selected VL CDR1, 2, and 3 amino acid sequences are shown as SEQ ID NO:213, 214, and 215, respectively, wherein the VH amino acid sequence is selected from the group consisting of SEQ ID NO:37, 38, 39, 63, 64, 65, 69, 70, 71, 216, 261, 262, 263, 264, 265, 266, and 267.
13. The nucleic acid according to claim 12, wherein the nucleic acid comprises a polynucleotide encoding a polypeptide, the polypeptide comprising an immunoglobulin light chain or a fragment thereof containing VL, and the VL comprises CDR1, 2, and 3 having amino acid sequences as shown in SEQ ID NO:19, 20, and 21, respectively.
14. The nucleic acid according to claim 12, wherein the nucleic acid comprises a polynucleotide encoding a polypeptide, the polypeptide comprising an immunoglobulin light chain or a fragment thereof containing VL, and the VL comprises CDR1, 2, and 3 having amino acid sequences as shown in SEQ ID NO:22, 23, and 24, respectively.
15. The nucleic acid according to claim 12, wherein the nucleic acid comprises a polynucleotide encoding a polypeptide, the polypeptide comprising an immunoglobulin light chain containing VL or a fragment thereof, and the VL comprises CDR1, 2, and 3 having the amino acid sequences shown in SEQ ID NO: 25, 26, and 27, respectively.
16. The nucleic acid according to any one of claims 8-15, wherein the VH specifically binds to human CCR8, mouse CCR8, or monkey CCR8 when paired with VL, or the VL specifically binds to human CCR8, mouse CCR8, or monkey CCR8 when paired with VH.
17. The nucleic acid according to any one of claims 8-16, wherein the immunoglobulin heavy chain or a fragment thereof is a human or humanized immunoglobulin heavy chain or a fragment thereof, and the immunoglobulin light chain or a fragment thereof is a human or humanized immunoglobulin light chain or a fragment thereof.
18. The nucleic acid according to any one of claims 8-17, wherein the nucleic acid encodes a single-chain variable fragment (scFv), a single-arm antibody, or a multispecific antibody (such as a bispecific antibody).
19. The nucleic acid according to any one of claims 8-18, wherein the nucleic acid is cDNA.
20. A vector, the vector comprising one or more nucleic acids according to any one of claims 8-19.
21. A vector, the vector comprising two nucleic acids according to any one of claims 8-19, wherein the vector encodes a VH region and a VL region, and the VH region and the VL region together bind to CCR8.
22. A pair of vectors, wherein each vector comprises one nucleic acid according to any one of claims 8-19, and the pair of vectors together encodes a VH region and a VL region, and the VH region and the VL region together bind to CCR8.
23. A cell, the cell comprising the vector according to claim 20 or 21, or the pair of vectors according to claim 22.
24. The cell according to claim 23, wherein the cell is a CHO cell.
25. A cell, the cell comprising one or more nucleic acids according to any one of claims 8-19.
26. A cell, the cell comprising two nucleic acids according to any one of claims 8-19.
27. The cell according to claim 26, wherein the two nucleic acids together encode a VH region and a VL region, and the VH region and the VL region together bind to CCR8.
28. A method for producing an antibody or an antigen-binding fragment thereof, the method comprising: (a) culturing the cell according to any one of claims 23-27 under conditions sufficient for the cell to produce the antibody or antigen-binding fragment; and (b) collecting the antibody or antigen-binding fragment produced by the cell.
29. An antibody or an antigen-binding fragment thereof that binds to CCR8, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) comprising an amino acid sequence having at least 80% identity to a selected VH sequence, and a light chain variable region (VL) comprising an amino acid sequence having at least 80% identity to a selected VL sequence, wherein the selected VH sequences are selected from the group consisting of SEQ ID NO:37, 38, 39, 63, 64, 65, 69, 70, 71, 216, 261, 262, 263, 264, 265, 266, and 267, wherein the selected VL sequences are selected from the group consisting of SEQ ID NO:40, 41, 42, 66, 67, and 68.
30. The antibody or antigen-binding fragment thereof according to claim 29, wherein the VH sequence and the VL sequence are one of the following: (1) the VH comprises the sequence of SEQ ID NO:37, and the VL comprises the sequence of SEQ ID NO:40; (2) the VH comprises the sequence of SEQ ID NO:38, and the VL comprises the sequence of SEQ ID NO:41; (3) the VH comprises the sequence of SEQ ID NO:39, and the VL comprises the sequence of SEQ ID NO:42; (4) the VH comprises the sequence of SEQ ID NO:37, and the VL comprises the sequence of SEQ ID NO:41; (5) the VH comprises the sequence of SEQ ID NO:37, and the VL comprises the sequence of SEQ ID NO:42; (6) the VH comprises the sequence of SEQ ID NO:38, and the VL comprises the sequence of SEQ ID NO:40; (7) the VH comprises the sequence of SEQ ID NO:38, and the VL comprises the sequence of SEQ ID NO:42; (8) the VH comprises the sequence of SEQ ID NO:39, and the VL comprises the sequence of SEQ ID NO:40; (9) the VH comprises the sequence of SEQ ID NO:39, and the VL comprises the sequence of SEQ ID NO:41; (10) the VH comprises the sequence of SEQ ID NO:37, and the VL comprises the sequence of SEQ ID NO:68; (11) the VH comprises the sequence of SEQ ID NO:63, and the VL comprises the sequence of SEQ ID NO:68; (12) the VH comprises the sequence of SEQ ID NO:63, and the VL comprises the sequence of SEQ ID NO:66; (13) the VH comprises the sequence of SEQ ID NO:65, and the VL comprises the sequence of SEQ ID NO:68; (14) the VH comprises the sequence of SEQ ID NO:64, and the VL comprises the sequence of SEQ ID NO:67; (15) the VH comprises the sequence of SEQ ID NO:63, and the VL comprises the sequence of SEQ ID NO:42; (16) the VH comprises the sequence of SEQ ID NO:216, and the VL comprises the sequence of SEQ ID NO:42; (17) The VH comprises the sequence of SEQ ID NO: 261, and the VL comprises the sequence of SEQ ID NO: 41; (18) The VH comprises the sequence of SEQ ID NO: 262, and the VL comprises the sequence of SEQ ID NO: 41; (19) The VH comprises the sequence of SEQ ID NO: 263, and the VL comprises the sequence of SEQ ID NO: 41; (20) The VH comprises the sequence of SEQ ID NO: 264, and the VL comprises the sequence of SEQ ID NO: 41; (21) The VH comprises the sequence of SEQ ID NO: 265, and the VL comprises the sequence of SEQ ID NO: 41; (22) The VH comprises the sequence of SEQ ID NO: 266, and the VL comprises the sequence of SEQ ID NO: 41; and (23) The VH comprises the sequence of SEQ ID NO: 267, and the VL comprises the sequence of SEQ ID NO:
41.
31. The antibody or antigen-binding fragment thereof according to claim 29 or 30, wherein the antibody or antigen-binding fragment specifically binds to human CCR8, mouse CCR8 or monkey CCR8.
32. The antibody or antigen-binding fragment thereof according to any one of claims 29-31, wherein the antibody or antigen-binding fragment is a human or humanized antibody or antigen-binding fragment thereof.
33. The antibody or antigen-binding fragment thereof according to any one of claims 29-32, wherein the antibody or antigen-binding fragment is a single-chain variable fragment (scFv), a single-arm antibody or a multispecific antibody (such as a bispecific antibody).
34. An antibody or antigen-binding fragment thereof that binds to CCR8, the antibody or antigen-binding fragment thereof comprising a heavy-chain variable region (VH) containing VH CDR1, 2, 3 and a light-chain variable region (VL) containing VL CDR1, 2, 3, wherein the VH CDR1, 2, 3 and the VL CDR1, 2, 3 are the same as the complementary determining regions in the antibody or antigen-binding fragment thereof according to any one of claims 1-7 and 29-33.
35. The antibody or antigen-binding fragment thereof according to claim 34, wherein the VH CDR1, 2, 3 are the same as the complementary determining regions in SEQ ID NO: 37, 38, 39, 63, 64, 65, 69, 70, 71, 216, 261, 262, 263, 264, 265, 266 or 267, and the VL CDR1, 2, 3 are the same as the complementary determining regions in SEQ ID NO: 40, 41, 42, 66, 67 or 68.
36. An antibody or antigen-binding fragment thereof that cross-competes with the antibody or antigen-binding fragment thereof according to any one of claims 1-7 and 29-35.
37. An antibody-drug conjugate, said antibody-drug conjugate comprising an antibody or an antigen-binding fragment thereof as described in any one of claims 1-7 and 29-36 covalently bound to a therapeutic agent.
38. The antibody-drug conjugate according to claim 37, wherein the therapeutic agent is a cytotoxic agent or a cell growth inhibitor.
39. A method of treating a subject having cancer, said method comprising: administering to the subject a therapeutically effective amount of a composition comprising an antibody or an antigen-binding fragment thereof as described in any one of claims 1-7 and 29-36, or an antibody-drug conjugate as described in claim 37 or 38.
40. The method according to claim 39, wherein the subject has a solid tumor.
41. The method according to claim 39 or 40, wherein the cancer is breast cancer, melanoma, non-small cell lung cancer, lung adenocarcinoma, colon cancer or colorectal cancer (e.g., colorectal adenocarcinoma).
42. The method according to any one of claims 39-41, wherein the cancer is resistant to treatment with a PD-1 pathway inhibitor.
43. The method according to any one of claims 39-42, wherein the method further comprises administering to the subject a PD-1 pathway inhibitor.
44. The method according to claim 43, wherein the PD-1 pathway inhibitor is an anti-PD-1 antibody (e.g., Pembrolizumab, Nivolumab or Cemiplimab).
45. The method according to claim 43, wherein the PD-1 pathway inhibitor is an anti-PD-L1 antibody (e.g., Atezolizumab, Avelumab or Durvalumab).
46. A method of reducing the tumor growth rate, said method comprising contacting the tumor cells with an effective amount of a composition comprising an antibody or an antigen-binding fragment thereof as described in any one of claims 1-7 and 29-36, or an antibody-drug conjugate as described in claim 37 or 38.
47. A method of killing tumor cells, said method comprising contacting the tumor cells with an effective amount of a composition comprising an antibody or an antigen-binding fragment thereof as described in any one of claims 1-7 and 29-36, or an antibody-drug conjugate as described in claim 37 or 38.
48. A pharmaceutical composition, said pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof as described in any one of claims 1-7 and 29-36 and a pharmaceutically acceptable carrier.
49. A pharmaceutical composition, said pharmaceutical composition comprising an antibody-drug conjugate as described in claim 37 or 38 and a pharmaceutically acceptable carrier.
Citation Information
Patent Citations
Expression of gag proteins from retroviruses in eucaryotic cells
EP0345242A2
A method of obtaining a retrovirus-containing fraction from retrovirus-containing cells
GB2200651A
Genetically modified non-human animals with humanized immunoglobulin locus
US20200390073A1
Modified vaccinia virus
US4603112A
Target specific cross-linked heteroantibodies
US4676980A
